WO1998046641A9 - Novel polypeptides within the growth factor superfamily - Google Patents
Novel polypeptides within the growth factor superfamilyInfo
- Publication number
- WO1998046641A9 WO1998046641A9 PCT/US1998/007603 US9807603W WO9846641A9 WO 1998046641 A9 WO1998046641 A9 WO 1998046641A9 US 9807603 W US9807603 W US 9807603W WO 9846641 A9 WO9846641 A9 WO 9846641A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tango
- nucleic acid
- polypeptide
- expression
- sequence
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 144
- 239000003102 growth factor Substances 0.000 title abstract description 10
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 128
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 120
- 230000014509 gene expression Effects 0.000 claims description 108
- 150000001875 compounds Chemical class 0.000 claims description 53
- 102000004965 antibodies Human genes 0.000 claims description 52
- 108090001123 antibodies Proteins 0.000 claims description 52
- 230000000694 effects Effects 0.000 claims description 49
- 229920001850 Nucleic acid sequence Polymers 0.000 claims description 26
- 239000002773 nucleotide Substances 0.000 claims description 25
- 125000003729 nucleotide group Chemical group 0.000 claims description 25
- 230000000295 complement Effects 0.000 claims description 24
- 201000010099 disease Diseases 0.000 claims description 23
- 241000282414 Homo sapiens Species 0.000 claims description 21
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 21
- 239000012472 biological sample Substances 0.000 claims description 19
- 239000000523 sample Substances 0.000 claims description 18
- 230000001105 regulatory Effects 0.000 claims description 16
- 210000001519 tissues Anatomy 0.000 claims description 15
- 230000000051 modifying Effects 0.000 claims description 14
- 241000700605 Viruses Species 0.000 claims description 13
- 239000003550 marker Substances 0.000 claims description 12
- 230000001594 aberrant Effects 0.000 claims description 11
- 108010045030 monoclonal antibodies Proteins 0.000 claims description 10
- 102000005614 monoclonal antibodies Human genes 0.000 claims description 10
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 9
- 241000701161 unidentified adenovirus Species 0.000 claims description 9
- 108010035563 Chloramphenicol O-Acetyltransferase Proteins 0.000 claims description 7
- 108020004440 Thymidine Kinase Proteins 0.000 claims description 7
- 102000006601 Thymidine Kinase Human genes 0.000 claims description 7
- 230000001965 increased Effects 0.000 claims description 7
- 102000009914 Adenosine deaminases Human genes 0.000 claims description 6
- 108091022188 Adenosine deaminases Proteins 0.000 claims description 6
- 108010027570 EC 2.4.2.22 Proteins 0.000 claims description 6
- 102000004419 dihydrofolate reductase family Human genes 0.000 claims description 6
- 108020001096 dihydrofolate reductase family Proteins 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 101710024922 hyg Proteins 0.000 claims description 6
- 101700014779 GLB1 Proteins 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 102000030951 Phosphotransferases Human genes 0.000 claims description 4
- 108091000081 Phosphotransferases Proteins 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 230000003247 decreasing Effects 0.000 claims description 4
- 230000004962 physiological condition Effects 0.000 claims description 4
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-Phosphoglyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 claims description 3
- 102000013563 Acid Phosphatase Human genes 0.000 claims description 3
- 108010051457 Acid Phosphatase Proteins 0.000 claims description 3
- 101710010587 CASP13 Proteins 0.000 claims description 3
- 241000701022 Cytomegalovirus Species 0.000 claims description 3
- 102100014497 GOLPH3 Human genes 0.000 claims description 3
- 101710008339 GOLPH3 Proteins 0.000 claims description 3
- 108010025815 Kanamycin Kinase Proteins 0.000 claims description 3
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 claims description 3
- 101700062818 NP Proteins 0.000 claims description 3
- 101710043203 P23p89 Proteins 0.000 claims description 3
- 229940014598 TAC Drugs 0.000 claims description 3
- 102000006646 aminoglycoside phosphotransferase family Human genes 0.000 claims description 3
- 238000005755 formation reaction Methods 0.000 claims description 3
- 101710034616 gVIII-1 Proteins 0.000 claims description 3
- 101700045377 mvp1 Proteins 0.000 claims description 3
- 241001430294 unidentified retrovirus Species 0.000 claims description 3
- 230000001809 detectable Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 102000015225 Connective Tissue Growth Factor Human genes 0.000 abstract description 4
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 abstract description 4
- 210000004027 cells Anatomy 0.000 description 91
- 102000004169 proteins and genes Human genes 0.000 description 52
- 108090000623 proteins and genes Proteins 0.000 description 52
- 235000018102 proteins Nutrition 0.000 description 50
- 238000000034 method Methods 0.000 description 40
- 229920000272 Oligonucleotide Polymers 0.000 description 33
- 108020004999 Messenger RNA Proteins 0.000 description 28
- 229920002106 messenger RNA Polymers 0.000 description 28
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 25
- 230000000692 anti-sense Effects 0.000 description 23
- 241001465754 Metazoa Species 0.000 description 22
- 239000000047 product Substances 0.000 description 21
- 229920002676 Complementary DNA Polymers 0.000 description 20
- 239000002299 complementary DNA Substances 0.000 description 19
- 238000009396 hybridization Methods 0.000 description 18
- 229920002477 rna polymer Polymers 0.000 description 18
- 229920001405 Coding region Polymers 0.000 description 17
- 239000000203 mixture Substances 0.000 description 17
- 239000002253 acid Substances 0.000 description 14
- 229920002033 ribozyme Polymers 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 13
- 230000027455 binding Effects 0.000 description 13
- 230000035897 transcription Effects 0.000 description 13
- 108020001507 fusion proteins Proteins 0.000 description 12
- 102000037240 fusion proteins Human genes 0.000 description 12
- 239000011780 sodium chloride Substances 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 10
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 9
- 108090000994 Catalytic RNA Proteins 0.000 description 9
- 230000004913 activation Effects 0.000 description 9
- 239000000074 antisense oligonucleotide Substances 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- 108020004511 Recombinant DNA Proteins 0.000 description 8
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 238000003752 polymerase chain reaction Methods 0.000 description 8
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 8
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 7
- 229920000978 Start codon Polymers 0.000 description 7
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 7
- 238000004166 bioassay Methods 0.000 description 7
- 230000001413 cellular Effects 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 7
- 230000002708 enhancing Effects 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 229960000060 monoclonal antibodies Drugs 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 230000003612 virological Effects 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 101710038160 MIA3 Proteins 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000038129 antigens Human genes 0.000 description 6
- 108091007172 antigens Proteins 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 108091006028 chimera Proteins 0.000 description 6
- 230000003899 glycosylation Effects 0.000 description 6
- 238000006206 glycosylation reaction Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000006011 modification reaction Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000001225 therapeutic Effects 0.000 description 6
- 101700058973 GAL4 Proteins 0.000 description 5
- 102100011539 LGALS4 Human genes 0.000 description 5
- 101710015850 LGALS4 Proteins 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 230000002068 genetic Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 238000010396 two-hybrid screening Methods 0.000 description 5
- -1 xantine Chemical compound 0.000 description 5
- YSAJFXWTVFGPAX-UHFFFAOYSA-N 2-[(2,4-dioxo-1H-pyrimidin-5-yl)oxy]acetic acid Chemical compound OC(=O)COC1=CNC(=O)NC1=O YSAJFXWTVFGPAX-UHFFFAOYSA-N 0.000 description 4
- 230000004568 DNA-binding Effects 0.000 description 4
- 210000001161 Embryo, Mammalian Anatomy 0.000 description 4
- 229920001941 Hammerhead ribozyme Polymers 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 101700040790 PH Proteins 0.000 description 4
- 102000005632 Single-Chain Antibodies Human genes 0.000 description 4
- 108010070144 Single-Chain Antibodies Proteins 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000000240 adjuvant Effects 0.000 description 4
- 230000000890 antigenic Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000003184 complementary RNA Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 230000003834 intracellular Effects 0.000 description 4
- 210000004962 mammalian cells Anatomy 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 108010055216 Anti-Idiotypic Antibodies Proteins 0.000 description 3
- 108020005544 Antisense RNA Proteins 0.000 description 3
- 210000001130 Astrocytes Anatomy 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 102000005720 Glutathione Transferase family Human genes 0.000 description 3
- 108010070675 Glutathione Transferase family Proteins 0.000 description 3
- 210000002216 Heart Anatomy 0.000 description 3
- 210000004408 Hybridomas Anatomy 0.000 description 3
- 108090000745 Immune Sera Proteins 0.000 description 3
- 229920002521 Macromolecule Polymers 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 210000002027 Muscle, Skeletal Anatomy 0.000 description 3
- 238000000636 Northern blotting Methods 0.000 description 3
- 241000276498 Pollachius virens Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 210000000952 Spleen Anatomy 0.000 description 3
- 210000001550 Testis Anatomy 0.000 description 3
- 210000001541 Thymus Gland Anatomy 0.000 description 3
- 229920002847 antisense RNA Polymers 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000002759 chromosomal Effects 0.000 description 3
- 238000010192 crystallographic characterization Methods 0.000 description 3
- 239000000032 diagnostic agent Substances 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 230000000415 inactivating Effects 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 150000002605 large molecules Chemical class 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 108091008117 polyclonal antibodies Proteins 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000001960 triggered Effects 0.000 description 3
- 101700021384 C2 Proteins 0.000 description 2
- 102100018113 C2 Human genes 0.000 description 2
- 102000001902 CC Chemokines Human genes 0.000 description 2
- 108010040471 CC Chemokines Proteins 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000701489 Cauliflower mosaic virus Species 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- 241000701959 Escherichia virus Lambda Species 0.000 description 2
- 230000035693 Fab Effects 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N Glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229960003180 Glutathione Drugs 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 101710007246 H3-3A Proteins 0.000 description 2
- 101700009603 HIS3 Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N Hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 2
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 2
- 210000000265 Leukocytes Anatomy 0.000 description 2
- 108090000157 Metallothionein Proteins 0.000 description 2
- 102000003792 Metallothionein Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000283898 Ovis Species 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 241000256251 Spodoptera frugiperda Species 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N Thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 241000723873 Tobacco mosaic virus Species 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000003042 antagnostic Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000000875 corresponding Effects 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 230000007045 gastrulation Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000010363 gene targeting Methods 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000001963 growth media Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- YACKEPLHDIMKIO-UHFFFAOYSA-L methylphosphonate(2-) Chemical compound CP([O-])([O-])=O YACKEPLHDIMKIO-UHFFFAOYSA-L 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000003472 neutralizing Effects 0.000 description 2
- 229920001894 non-coding RNA Polymers 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000000865 phosphorylative Effects 0.000 description 2
- 108060002324 polC Proteins 0.000 description 2
- 230000002335 preservative Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000002829 reduced Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
- 230000002103 transcriptional Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- CADQNXRGRFJSQY-UOWFLXDJSA-N (2R,3R,4R)-2-fluoro-2,3,4,5-tetrahydroxypentanal Chemical compound OC[C@@H](O)[C@@H](O)[C@@](O)(F)C=O CADQNXRGRFJSQY-UOWFLXDJSA-N 0.000 description 1
- NKCXQMYPWXSLIZ-PSRDDEIFSA-N (2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-3-m Chemical compound O=C([C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)[C@@H](C)O)[C@@H](C)O)C(C)C)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O NKCXQMYPWXSLIZ-PSRDDEIFSA-N 0.000 description 1
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- RFLVMTUMFYRZCB-UHFFFAOYSA-N 1-methylguanine Chemical compound O=C1N(C)C(N)=NC2=C1N=CN2 RFLVMTUMFYRZCB-UHFFFAOYSA-N 0.000 description 1
- WJNGQIYEQLPJMN-IOSLPCCCSA-N 1-methylinosine Chemical compound C1=NC=2C(=O)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WJNGQIYEQLPJMN-IOSLPCCCSA-N 0.000 description 1
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 2,6-Diaminopurine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
- HLYBTPMYFWWNJN-UHFFFAOYSA-N 2-(2,4-dioxo-1H-pyrimidin-5-yl)-2-hydroxyacetic acid Chemical compound OC(=O)C(O)C1=CNC(=O)NC1=O HLYBTPMYFWWNJN-UHFFFAOYSA-N 0.000 description 1
- XMSMHKMPBNTBOD-UHFFFAOYSA-N 2-(dimethylamino)-3,7-dihydropurin-6-one Chemical compound N1C(N(C)C)=NC(=O)C2=C1N=CN2 XMSMHKMPBNTBOD-UHFFFAOYSA-N 0.000 description 1
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 1
- FZWGECJQACGGTI-UHFFFAOYSA-N 2-imino-7-methyl-1,2,3,7-tetrahydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 1
- SMADWRYCYBUIKH-UHFFFAOYSA-N 2-methyl-7H-purin-6-amine Chemical compound CC1=NC(N)=C2NC=NC2=N1 SMADWRYCYBUIKH-UHFFFAOYSA-N 0.000 description 1
- KOLPWZCZXAMXKS-UHFFFAOYSA-N 3-methylcytosine Chemical compound CN1C(N)=CC=NC1=O KOLPWZCZXAMXKS-UHFFFAOYSA-N 0.000 description 1
- GJAKJCICANKRFD-UHFFFAOYSA-N 4-acetyl-4-amino-1,3-dihydropyrimidin-2-one Chemical compound CC(=O)C1(N)NC(=O)NC=C1 GJAKJCICANKRFD-UHFFFAOYSA-N 0.000 description 1
- OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1H-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- MQJSSLBGAQJNER-UHFFFAOYSA-N 5-(methylaminomethyl)-1H-pyrimidine-2,4-dione Chemical compound CNCC1=CNC(=O)NC1=O MQJSSLBGAQJNER-UHFFFAOYSA-N 0.000 description 1
- LQLQRFGHAALLLE-UHFFFAOYSA-N 5-Bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-Methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
- WPYRHVXCOQLYLY-UHFFFAOYSA-N 5-[(methoxyamino)methyl]-2-sulfanylidene-1H-pyrimidin-4-one Chemical compound CONCC1=CNC(=S)NC1=O WPYRHVXCOQLYLY-UHFFFAOYSA-N 0.000 description 1
- VKLFQTYNHLDMDP-PNHWDRBUSA-N 5-carboxymethylaminomethyl-2-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)NC(=O)C(CNCC(O)=O)=C1 VKLFQTYNHLDMDP-PNHWDRBUSA-N 0.000 description 1
- ZFTBZKVVGZNMJR-UHFFFAOYSA-N 5-chlorouracil Chemical compound ClC1=CNC(=O)NC1=O ZFTBZKVVGZNMJR-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- KSNXJLQDQOIRIP-UHFFFAOYSA-N 5-iodouracil Chemical compound IC1=CNC(=O)NC1=O KSNXJLQDQOIRIP-UHFFFAOYSA-N 0.000 description 1
- KELXHQACBIUYSE-UHFFFAOYSA-N 5-methoxy-1H-pyrimidine-2,4-dione Chemical compound COC1=CNC(=O)NC1=O KELXHQACBIUYSE-UHFFFAOYSA-N 0.000 description 1
- ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1H-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 description 1
- DCPSTSVLRXOYGS-UHFFFAOYSA-N 6-amino-1H-pyrimidine-2-thione Chemical compound NC1=CC=NC(S)=N1 DCPSTSVLRXOYGS-UHFFFAOYSA-N 0.000 description 1
- 101710006746 7.5K Proteins 0.000 description 1
- 102100001249 ALB Human genes 0.000 description 1
- 101710027066 ALB Proteins 0.000 description 1
- 102100007409 APRT Human genes 0.000 description 1
- 101710006647 APRT Proteins 0.000 description 1
- 108010024223 Adenine Phosphoribosyltransferase Proteins 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K Aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 229960001230 Asparagine Drugs 0.000 description 1
- 229960005261 Aspartic Acid Drugs 0.000 description 1
- 241001367049 Autographa Species 0.000 description 1
- 210000003719 B-Lymphocytes Anatomy 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 210000001218 Blood-Brain Barrier Anatomy 0.000 description 1
- 210000000988 Bone and Bones Anatomy 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- LLWPKTDSDUQBFY-UHFFFAOYSA-N C(=O)(O)CC=1C(NC(NC=1CN)=O)=O Chemical compound C(=O)(O)CC=1C(NC(NC=1CN)=O)=O LLWPKTDSDUQBFY-UHFFFAOYSA-N 0.000 description 1
- 101000560403 CCN2 Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229960004424 Carbon Dioxide Drugs 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 210000000170 Cell Membrane Anatomy 0.000 description 1
- 210000000349 Chromosomes Anatomy 0.000 description 1
- 210000001072 Colon Anatomy 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- YPHMISFOHDHNIV-FSZOTQKASA-N Cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
- ZAQJHHRNXZUBTE-WUJLRWPWSA-N D-xylulose Chemical compound OC[C@@H](O)[C@H](O)C(=O)CO ZAQJHHRNXZUBTE-WUJLRWPWSA-N 0.000 description 1
- 101710007887 DHFR Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N Dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 229940087091 Dichlorotetrafluoroethane Drugs 0.000 description 1
- OIVLITBTBDPEFK-UHFFFAOYSA-N Dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 108010091358 EC 2.4.2.8 Proteins 0.000 description 1
- 210000001671 Embryonic Stem Cells Anatomy 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010093099 Endoribonucleases Proteins 0.000 description 1
- 102000002494 Endoribonucleases Human genes 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 229940079360 Enema for Constipation Drugs 0.000 description 1
- 229940088598 Enzyme Drugs 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 210000003743 Erythrocytes Anatomy 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 108050001049 Extracellular protein Proteins 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 229960002949 Fluorouracil Drugs 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102100016790 HPRT1 Human genes 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 229960000310 ISOLEUCINE Drugs 0.000 description 1
- 102000018358 Immunoglobulins Human genes 0.000 description 1
- 108060003951 Immunoglobulins Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- UGQMRVRMYYASKQ-KMPDEGCQSA-N Inosine Natural products O[C@H]1[C@H](O)[C@@H](CO)O[C@@H]1N1C(N=CNC2=O)=C2N=C1 UGQMRVRMYYASKQ-KMPDEGCQSA-N 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 229920001320 Leader sequence (mRNA) Polymers 0.000 description 1
- 229940067606 Lecithin Drugs 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 108060001084 Luciferase family Proteins 0.000 description 1
- 108010047357 Luminescent Proteins Proteins 0.000 description 1
- 102000006830 Luminescent Proteins Human genes 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241001599018 Melanogaster Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 210000000214 Mouth Anatomy 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 229960000951 Mycophenolic Acid Drugs 0.000 description 1
- 210000000066 Myeloid Cells Anatomy 0.000 description 1
- HYVABZIGRDEKCD-UHFFFAOYSA-N N(6)-dimethylallyladenine Chemical compound CC(C)=CCNC1=NC=NC2=C1N=CN2 HYVABZIGRDEKCD-UHFFFAOYSA-N 0.000 description 1
- XJVXMWNLQRTRGH-UHFFFAOYSA-N N-(3-methylbut-3-enyl)-2-methylsulfanyl-7H-purin-6-amine Chemical compound CSC1=NC(NCCC(C)=C)=C2NC=NC2=N1 XJVXMWNLQRTRGH-UHFFFAOYSA-N 0.000 description 1
- SGSSKEDGVONRGC-UHFFFAOYSA-N N2-Methylguanine Chemical compound O=C1NC(NC)=NC2=C1N=CN2 SGSSKEDGVONRGC-UHFFFAOYSA-N 0.000 description 1
- 229920002332 Noncoding DNA Polymers 0.000 description 1
- 210000001331 Nose Anatomy 0.000 description 1
- 210000001672 Ovary Anatomy 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 210000000496 Pancreas Anatomy 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 229960005190 Phenylalanine Drugs 0.000 description 1
- 229940067631 Phospholipids Drugs 0.000 description 1
- LLKYUHGUYSLMPA-UHFFFAOYSA-N Phosphoramidite Chemical compound NP([O-])[O-] LLKYUHGUYSLMPA-UHFFFAOYSA-N 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 210000002826 Placenta Anatomy 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 210000002307 Prostate Anatomy 0.000 description 1
- 108010078762 Protein Precursors Proteins 0.000 description 1
- 102000014961 Protein Precursors Human genes 0.000 description 1
- 210000003324 RBC Anatomy 0.000 description 1
- 102000007312 Recombinant Proteins Human genes 0.000 description 1
- 108010033725 Recombinant Proteins Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 101710043164 Segment-4 Proteins 0.000 description 1
- 229920000972 Sense strand Polymers 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 229940083575 Sodium Dodecyl Sulfate Drugs 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229940075582 Sorbic Acid Drugs 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 229940032147 Starch Drugs 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- ZEMGGZBWXRYJHK-UHFFFAOYSA-N Thiouracil Chemical compound O=C1C=CNC(=S)N1 ZEMGGZBWXRYJHK-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N Trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 101700073917 UP01 Proteins 0.000 description 1
- 108020003635 Untranslated Regions Proteins 0.000 description 1
- 229920000146 Untranslated region Polymers 0.000 description 1
- 229940035893 Uracil Drugs 0.000 description 1
- 101700038759 VP1 Proteins 0.000 description 1
- 208000007089 Vaccinia Diseases 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 108091006072 activator proteins Proteins 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000259 anti-tumor Effects 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 125000000089 arabinosyl group Chemical class C1([C@@H](O)[C@H](O)[C@H](O)CO1)* 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000001580 bacterial Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000000749 co-immunoprecipitation Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000005289 controlled pore glass Substances 0.000 description 1
- 230000003412 degenerative Effects 0.000 description 1
- 230000004059 degradation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000000368 destabilizing Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000007435 diagnostic evaluation Methods 0.000 description 1
- ANCLJVISBRWUTR-UHFFFAOYSA-M diaminophosphinate Chemical compound NP(N)([O-])=O ANCLJVISBRWUTR-UHFFFAOYSA-M 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
- RJBIAAZJODIFHR-UHFFFAOYSA-L dioxidothiophosphorylamine Chemical compound NP([O-])([O-])=S RJBIAAZJODIFHR-UHFFFAOYSA-L 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000013080 embryo development ending in birth or egg hatching Effects 0.000 description 1
- 230000013144 embryo development ending in seed dormancy Effects 0.000 description 1
- 210000002257 embryonic structures Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 108090001102 hammerhead ribozyme Proteins 0.000 description 1
- 101700005460 hemA Proteins 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 125000003372 histidine group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 102000021184 human CCN2 protein Human genes 0.000 description 1
- 230000002209 hydrophobic Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001976 improved Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 230000001665 lethal Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 media Substances 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- IZAGSTRIDUNNOY-UHFFFAOYSA-N methyl 2-[(2,4-dioxo-1H-pyrimidin-5-yl)oxy]acetate Chemical compound COC(=O)COC1=CNC(=O)NC1=O IZAGSTRIDUNNOY-UHFFFAOYSA-N 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000000546 pharmaceutic aid Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000001402 polyadenylating Effects 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001323 posttranslational Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 108091007521 restriction endonucleases Proteins 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- DYAHQFWOVKZOOW-UHFFFAOYSA-N sarin Chemical compound CC(C)OP(C)(F)=O DYAHQFWOVKZOOW-UHFFFAOYSA-N 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- WSWCOQWTEOXDQX-UHFFFAOYSA-N sorbic acid Chemical compound CC=CC=CC(O)=O WSWCOQWTEOXDQX-UHFFFAOYSA-N 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000004083 survival Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000005400 testing for adjacent nuclei with gyration operator Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000224 toxic side effect Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 108091005683 transmembrane proteins Proteins 0.000 description 1
- 102000035402 transmembrane proteins Human genes 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 239000011778 trisodium citrate Substances 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- WCNMEQDMUYVWMJ-JPZHCBQBSA-N wybutoxosine Chemical compound C1=NC=2C(=O)N3C(CC([C@H](NC(=O)OC)C(=O)OC)OO)=C(C)N=C3N(C)C=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WCNMEQDMUYVWMJ-JPZHCBQBSA-N 0.000 description 1
Definitions
- the size and differentiated characteristics of cellular compartments are controlled in part by the availability of extracellular growth factors. These growth factors can influence cellular replication, cell survival, as well as the function of differentiated end cells.
- the ability to control the expansion of specific cell types in vivo has demonstrated clinical utility, the best examples being the stimulation of red and white blood cell production by erythropoietin and granulocyte colony stimulating factor, respectively.
- the utility of growth factors for the treatment of other human disorders e.g., neurodegeneration
- TSG twisted gastrulation gene
- mRNA TSG messenger RNA
- CTGF connective tissue growth factor
- PDGF platelet derived growth factor
- the invention relates to the discovery and characterization of Tango-67, a new soluble growth factor.
- a form of Tango-67 described herein is a 224 amino acid, cysteine rich polypeptide.
- Northern blot analysis of Tango-67 mRNA reveals that it is present at varying levels in a wide variety of tissues.
- the invention features an isolated nucleic acid molecule encoding a Tango-67 polypeptide.
- the isolated nucleic acid molecule encodes the secreted form of human Tango- 67, or a polypeptide having sequence that is at least 85% identical to the sequence of SEQ ID NO : 2.
- the isolated nucleic acid molecule claim 1 includes a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 2; and includes the nucleotide sequence of between nucleotide 182 and 850, inclusive, of SEQ ID NO : 1.
- the isolated nucleic acid molecule encoding Tango- 67 hybridizes to a nucleic acid molecule having the sequence of nucleotides 182 to 850, inclusive, of SEQ ID NO : 1 or its complement. In other embodiments, the hybridization occurs under stringent conditions.
- the isolated nucleic acid molecule encoding Tango- 67 encodes a Tango- 67 polypeptide capable of promoting cell proliferation and/or differentiation.
- the invention also features a host cell which includes and isolated nucleic acid molecule encoding Tango-67, a nucleic acid vector (e.g., an expression vector, a vector which includes a regulatory element, a vector which includes a regulatory element selected from the group consisting of the cytomegalovirus hCMV immediate early gene, the early promoter of SV40 adenovirus, the late promoter of SV40 adenovirus, the lac system, the trp system, the TAC system, the TRC system, the major operator and promoter regions of phage ⁇ , the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase, the promoters of acid phosphatase, and the promoters of the yeast ⁇ .-mating factors, vector which includes a regulatory element which directs tissue
- the invention features a substantially pure Tango-67 polypeptide (e.g., a Tango-67 polypeptide that is soluble under physiological conditions, a Tango- 67 polypeptide which includes a signal sequence, a Tango-67 polypeptide that stimulated proliferation and/or differentiation of a cell, a Tango- 67 polypeptide that includes an amino acid sequence that is at least 85% identical to the amino acid sequence of SEQ ID NO: 2, a Tango-67 polypeptide that includes an amino acid sequence that is at least 90% identical to the amino acid sequence of of SEQ ID NO : 2 , a Tango- 67 polypeptide that includes an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 2, and a Tango- 67 polypeptide that includes an amino acid sequence that is identical to the amino acid sequence of SEQ ID NO: 2.
- a Tango-67 polypeptide that is soluble under physiological conditions, a Tango- 67 polypeptide which includes a signal sequence, a Tang
- the invention features a substantially pure polypeptide which includes a first portion and a second portion, the first portion including a Tango-67 polypeptide and the second portion including a detectable marker.
- the invention also features an antibody that selectively binds to a Tango-67 polypeptide (e.g., a monoclonal antibody) .
- a Tango-67 polypeptide e.g., a monoclonal antibody
- the invention also features a pharmaceutical composition which includes a Tango-67 polypeptide.
- Also included in the invention are: a method for detecting Tango- 67 in a sample, the method including: (a) obtaining a biological sample;
- the invention features a method of identifying a compound that modulates the expression of Tango-67, the method including comparing the level of expression of Tango-67 in a cell in the presence and absence of a selected compound, wherein a difference in the level of expression in the presence and absence of the selected compound indicates that the selected compound modulates the expression of Tango- 67.
- the invention features, a method of identifying a compound that modulates the activity of Tango- 67, the method including comparing the level of activity of Tango-67 m a cell m the presence and absence of a selected compound, wherein a difference m the level of activity m the presence and absence of the selected compound indicates that the selected compound modulates the activity of Tango-67.
- the invention features a method for treating a patient suffering from a disorder associated with excessive expression or activity of Tango- 67, the method including administering to the patient a compound which inhibits expression or activity of Tango- 67.
- the invention also features a method for treating a patient suffering from a disorder associated with insufficient expression or activity of Tango-67, the method including administering to the patient a compound which increases expression or activity of Tango-67.
- the invention also features a method for diagnosing a disorder associated with aberrant expression of Tango- 67, the method including obtaining a biological sample from a patient and measuring Tango- 67 expression m the biological sample, wherein increased or decreased Tango-67 expression m the biological sample compared to a control indicates that the patient suffers from a disorder associated with aberrant expression of Tango-67.
- the invention features a method for diagnosing a disorder associated with aberrant activity of Tango- 67, the method including obtaining a biological sample from a patient and measuring Tango- 67 activity m the biological sample, wherein increased or decreased Tango-67 activity m the biological sample compared to a control indicates that the patient suffers from a disorder associated with aberrant activity of Tango- 67.
- the invention encompasses isolated nucleic acid molecules encoding Tango- 67 or a fragment thereof, vectors containing these nucleic acid molecules, cells harboring recombined DNA encoding Tango- 67, fusion proteins which include Tango- 67, transgenic animals which express Tango- 67, recombinant knock-out animals which fail to express Tango-67.
- nucleic acid molecules encoding the polypeptide shown in the Figure (SEQ ID NO: 2) .
- the invention encompasses nucleic acids that have a sequence that is substantially identical to a Tango-67 nucleic acid sequence.
- a nucleic acid which is substantially identical to a given reference nucleic acid molecule is hereby defined as a nucleic acid having a sequence that has at least 85%, preferably 90%, and more preferably 95%, 98%, 99% or more identity to the sequence of the given reference nucleic acid molecule, e.g., the nucleic acid sequence of SEQ ID NO : 1.
- a polypeptide which is "substantially identical" to a given reference polypeptide molecule is hereby defined as a polypeptide having a sequence that has at least 85%, preferably 90%, and more preferably 95%, 98%, 99% or more identity to the sequence of the given reference polypeptide sequence, e.g., the polypeptide sequence of SEQ ID NO:2.
- the nucleic acid molecules of the invention can be inserted into transcription and/or translation vectors, as described below, which will facilitate expression of the insert.
- the nucleic acid molecules and the polypeptides they encode can be used directly as diagnostic or therapeutic agents, or (in the case of a polypeptide) can be used to generate antibodies that, in turn, are therapeutically useful. Accordingly, expression vectors containing the nucleic acid molecules of the invention, cells transfected with these vectors, the polypeptides expressed, and antibodies generated, against either the entire polypeptide or an antigenic fragment thereof, are among the preferred embodiments.
- a transfected cell is any cell into which (or into an ancestor of which) has been introduced, by means of recombinant DNA techniques, a nucleic acid encoding a polypeptide of the invention (e.g., a Tango-67 polypeptide) .
- An isolated nucleic acid molecule is a nucleic acid molecule that is separated from the 5' and 3' coding sequences with which it is immediately contiguous in the naturally occurring genome of an organism. Isolated nucleic acid molecule include nucleic acid molecule which are not naturally occurring, e.g., nucleic acid molecules created by recombinant DNA techniques .
- nucleic acid molecule encompasses both RNA and DNA, including cDNA, genomic DNA, and synthetic (e.g., chemically synthesized) DNA. Where single- stranded, the nucleic acid may be a sense strand or an antisense strand.
- the invention also encompasses nucleic acid molecules that hybridize, preferably under stringent conditions, to a nucleic acid molecule encoding a Tango- 67 polypeptide (e.g., a nucleic acid molecule having the sequence shown in SEQ ID NO : 1 or a nucleic acid molecule having the sequence of the Tango- 67 encoding portion of the sequence of SEQ ID N0:1) .
- a nucleic acid molecule e.g., a nucleic acid molecule having the sequence shown in SEQ ID NO : 1 or a nucleic acid molecule having the sequence of the Tango- 67 encoding portion of the sequence of SEQ ID N0:1 .
- the hybridizing nucleic acid molecule consists of 400, more preferably 200 nucleotides.
- Preferred hybridizing nucleic acid molecules have an activity possessed by Tango-67, e.g., the ability to increase proliferation and/or differentiation of cells.
- the invention also features substantially pure or isolated Tango-67 polypeptides, including those that correspond to various functional domains of Tango-67, or fragments thereof.
- the polypeptides of the invention encompass ammo acid sequences that are substantially identical to the ammo acid sequence shown the Figure (SEQ ID NO: 2) .
- polypeptides of the invention can also be chemically synthesized, or they can be purified from tissues which they are naturally expressed, according to standard biochemical methods of purification.
- polypeptides which possess one or more of the biological functions or activities of Tango-67. These functions include the ability to bind some or all of the proteins which normally bind to Tango-67.
- a functional polypeptide is also considered within the scope of the invention if it serves as an antigen for production of antibodies that specifically bind to Tango-67. In many cases, functional polypeptides retain one or more domains present m the naturally-occurring form of the polypeptide .
- the functional polypeptides may contain a primary ammo acid sequence that has been modified from those disclosed herein. Preferably these modifications consist of conservative ammo acid substitutions, as described herein.
- Tango-67 polypeptides includes full-length, naturally occurring Tango- 67 protein (with or without a signal sequence) , as well a reco bmantly or synthetically produced polypeptide that correspond to a full-length naturally occurring Tango-67 protein or to particular domains or portions of a naturally occurring protein.
- the term also encompasses mature Tango- 67 which has an added ammo-terminal methionme (useful for expression in prokaryotic cells) .
- purified refers to a nucleic acid or peptide that is substantially free of cellular material, viral material, or culture medium when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized.
- Polypeptides or other compounds of interest are said to be "substantially pure” when they are within preparations that are at least 60% by weight (dry weight) the compound of interest.
- the preparation is at least 75%, more preferably at least 90%, and most preferably at least 99%, by weight the compound of interest .
- Purity can be measured by any appropriate standard method, for example, by column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis.
- a polypeptide or nucleic acid molecule is "substantially identical" to a reference polypeptide or nucleic acid molecule if it has a sequence that is at least 85%, preferably at least 90%, and more preferably at least 95%, 98%, or 99% identical to the sequence of the reference polypeptide or nucleic ac d molecule.
- a particular polypeptide is said to have a specific percent identity to a reference polypeptide of a defined length, the percent identity is relative to the reference peptide.
- a peptide that is 50% identical to a reference polypeptide that is 100 ammo acids long can be a 50 ammo acid polypeptide that is completely identical to a 50 ammo acid long portion of the reference polypeptide. It might also be a 100 ammo acid long polypeptide which is 50% identical to the reference polypeptide over its entire length.
- many other polypeptides will meet the same criteria.
- non- identical positions are preferably, but not necessarily, conservative substitutions for the reference sequence.
- Conservative substitutions typically include substitutions within the following groups: glycine and alanine; valine, isoleucine, and leucine; aspartic acid and glutamic acid; asparagine and glutamine; serine and threonine; lysine and arginine; and phenylalanine and tyrosine .
- the length of the reference polypeptide sequence will generally be at least 16 amino acids, preferably at least 20 amino acids, more preferably at least 25 amino acids, and most preferably 35 amino acids, 50 amino acids, or 100 amino acids.
- the length of the reference nucleic acid sequence will generally be at least 50 nucleotides, preferably at least 60 nucleotides, more preferably at least 75 nucleotides, and most preferably 100 nucleotides or 300 nucleotides.
- Sequence identity can be measured using sequence analysis software (for example, the Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, WI 53705) , with the default parameters as specified therein.
- the nucleic acid molecules of the invention can be inserted into a vector, as described below, which will facilitate expression of the insert.
- the nucleic acid molecules and the polypeptides they encode can be used directly as diagnostic or therapeutic agents, or can be used (directly in the case of the polypeptide or indirectly in the case of a nucleic acid molecule) to generate antibodies that, in turn, are clinically useful as a therapeutic or diagnostic agent.
- vectors containing the nucleic acid of the invention, cells transfected with these vectors, the polypeptides expressed, and antibodies generated, against either the entire polypeptide or an antigenic fragment thereof, are among the preferred embodiments.
- transformed cell means a cell into which (or into an ancestor of which) has been introduced, by means of recombinant DNA techniques, a nucleic acid molecule encoding a polypeptide of the invention.
- the invention also features antibodies, e.g., monoclonal, polyclonal, and engineered antibodies, which specifically bind Tango-67.
- specifically binds is meant an antibody that recognizes and binds to a particular antigen, e.g., the Tango-67 polypeptide of the invention, but which does not substantially recognize or bind to other molecules in a sample, e.g., a biological sample, which includes Tango-67.
- the invention also features antagonists and agonists of Tango- 67 that can inhibit or enhance one or more of the functions or activities of Tango-67, respectively.
- Suitable antagonists can include small molecules (i.e., molecules with a molecular weight below about 500), large molecules (i.e., molecules with a molecular weight above about 500) , antibodies that bind and "neutralize" Tango-67 (as described below) , polypeptides which compete with a native form of Tango- 67 for binding to a protein, e.g., the Tango-67 receptor, and nucleic acid molecules that interfere with transcription of Tango- 67 (for example, antisense nucleic acid molecules and ribozymes) .
- Agonists of Tango- 67 also include small and large molecules, and antibodies other than "neutralizing" antibodies.
- the invention also features molecules which can increase or decrease the expression of Tango-67 (e.g., by influencing transcription or translation) .
- Small molecules i.e., molecules with a molecular weight below about 500
- large molecules i.e., molecules with a molecular weight above about 500
- nucleic acid molecules that can be used to inhibit the expression of Tango-67 (for example, antisense and ribozyme molecules) or to enhance their expression (for example, expression constructs that place nucleic acid sequences encoding Tango-67 under the control of a strong promoter system)
- transgenic animals that express a Tango- 67 transgene.
- the invention features substantially pure polypeptides that functionally interact with Tango- 67, e.g., a Tango-67 receptor, and the nucleic acid molecules that encode them.
- the invention encompasses methods for treating disorders associated with aberrant expression or activity of Tango-67.
- the invention includes methods for treating disorders associated with excessive expression or activity of Tango-67. Such methods entail administering a compound which decreases the expression or activity of Tango-67.
- the invention also includes methods for treating disorders associated with insufficient expression of Tango-67. These methods entail administering a compound which increases the expression or activity of Tango- 67.
- the invention also features methods for detecting a Tango- 67 polypeptide. Such methods include: obtaining a biological sample; contacting the sample with an antibody that specifically binds Tango- 67 under conditions which permit specific binding; and detecting any antibody-Tango-67 complexes formed.
- the present invention encompasses methods and compositions for the diagnostic evaluation, typing, and prognosis of disorders associated with inappropriate expression or activity of Tango-67.
- the nucleic acid molecules of the invention can be used as diagnostic hybridization probes to detect, for example, inappropriate expression of Tango- 67 or mutations in the Tango- 67 gene. Such methods may be used to classify cells by the level of Tango-67 expression.
- nucleic acid molecules can be used as primers for diagnostic PCR analysis for the identification of gene mutations, allelic variations and regulatory defects in the Tango- 67 gene.
- the present invention further provides for diagnostic kits for the practice of such methods.
- the invention features methods of identifying compounds that modulate the expression or activity of Tango-67 by assessing the expression or activity of Tango- 67 in the presence and absence of a selected compound. A difference in the level of expression or activity of Tango- 67 in the presence and absence of the selected compound indicates that the selected compound is capable of modulating expression or activity or Tango-67.
- Expression can be assessed either at the level of gene expression (e.g., by measuring mRNA) or protein expression by techniques that are well known to skilled artisans.
- the activity of Tango-67 can be assessed functionally, i.e., by assaying the ability of the compound to inhibit proliferation of myeloid cells.
- the Figure is a depiction of the nucleotide sequence encoding Tango-67 and 3' and 5' non-translated sequence (SEQ ID NO:l) and the amino acid sequence (SEQ ID NO: 2) of Tango- 67.
- Tango-67 is a new member of the growth factor superfamily. At the protein sequence level, Tango-67 is related to the product of the drosophila twisted gastrulation gene and human connective tissue growth factor .
- the Tango-67 nucleic acid molecules of the invention can be cDNA, genomic DNA, synthetic DNA, or
- RNA can be double-stranded or single-stranded (i.e., either a sense or an antisense strand) . Fragments of these molecules are also considered within the scope of the invention, and can be produced, for example, by the polymerase chain reaction (PCR) or generated by treatment with one or more restriction endonucleases .
- a ribonucleic acid (RNA) molecule can be produced by in vi tro transcription.
- the nucleic acid molecules encode polypeptides that, regardless of length, are soluble under normal physiological conditions.
- nucleic acid molecules of the invention can contain naturally occurring sequences, or sequences that differ from those that occur naturally, but, due to the degeneracy of the genetic code, encode the same polypeptide (for example, the polypeptide of SEQ ID NO: 2) .
- these nucleic acid molecules are not limited to sequences that only encode polypeptides, and thus, can include some or all of the non-coding sequences that lie upstream or downstream from a coding sequence .
- nucleic acid molecules of the invention can be synthesized (for example, by phosphoramidite-based synthesis) or obtained from a biological cell, such as the cell of a mammal.
- the nucleic acids can be those of a human, mouse, rat, guinea pig, cow, sheep, horse, pig, rabbit, monkey, dog, or cat. Combinations or modifications of the nucleotides within these types of nucleic acids are also encompassed.
- the isolated nucleic acid molecules of the invention encompass fragments that are not found as such in the natural state.
- the invention encompasses recombinant molecules, such as those in which a nucleic acid molecule (for example, an isolated nucleic acid molecule encoding Tango- 67) is incorporated into a vector (for example, a plasmid or viral vector) or into the genome of a heterologous cell (or the genome of a homologous cell, at a position other than the natural chromosomal location) .
- a nucleic acid molecule for example, an isolated nucleic acid molecule encoding Tango- 67
- a vector for example, a plasmid or viral vector
- Recombinant nucleic acid molecules and uses therefor are discussed further below.
- nucleic acid molecules of the invention encode or act as antisense molecules, they can be used for example, to regulate translation of Tango-67.
- Techniques associated with detection or regulation of Tango- 67 expression are well known to skilled artisans and can be used to diagnose and/or treat inflammation or disorders associated with cellular proliferation. These nucleic acid molecules are discussed further below in the context of their clinical utility.
- the invention also encompasses nucleic acid molecules that hybridize under stringent conditions to a nucleic acid molecule encoding a Tango- 67 polypeptide.
- the cDNA sequence described herein (SEQ ID NO:l) can be used to identify these nucleic acids, which include, for example, nucleic acids that encode homologous polypeptides in other species, and splice variants of the Tango-67 gene in humans or other mammals. Accordingly, the invention features methods of detecting and isolating these nucleic acid molecules.
- a sample for example, a nucleic acid library, such as a cDNA or genomic library
- a Tango- 67-specific probe for example, a fragment of SEQ ID NO : 1 that is at least 12 nucleotides long
- the probe will selectively hybridize to nucleic acids encoding related polypeptides (or to complementary sequences thereof) .
- the term “selectively hybridize” is used to refer to an event in which a probe binds to nucleic acids encoding Tango- 67 (or to complementary sequences thereof) to a detectably greater extent than to nucleic acids encoding other C-C chemokines (or to complementary sequences thereof) .
- the probe which can contain at least 12 (for example, 15, 25, 50, 100, or 200 nucleotides) can be produced using any of several standard methods (see, for example, Ausubel et al., "Current Protocols in Molecular Biology, Vol.
- the probe can be generated using PCR amplification methods in which oligonucleotide primers are used to amplify a Tango- 67-specific nucleic acid sequence (for example, a nucleic acid encoding the chemokine-like domain) that can be used as a probe to screen a nucleic acid library, as described in Example 1 below, and thereby detect nucleic acid molecules (within the library) that hybridize to the probe .
- oligonucleotide primers are used to amplify a Tango- 67-specific nucleic acid sequence (for example, a nucleic acid encoding the chemokine-like domain) that can be used as a probe to screen a nucleic acid library, as described in Example 1 below, and thereby detect nucleic acid molecules (within the library) that hybridize to the probe .
- One single-stranded nucleic acid is said to hybridize to another if a duplex forms between them. This occurs when one nucleic acid contains a sequence that is the reverse and complement of the other (this same arrangement gives rise to the natural interaction between the sense and antisense strands of DNA in the genome and underlies the configuration of the "double helix") . Complete complementarity between the hybridizing regions is not required in order for a duplex to form; it is only necessary that the number of paired bases is sufficient to maintain the duplex under the hybridization conditions used.
- hybridization conditions are of low to moderate stringency. These conditions favor specific interactions between completely complementary sequences, but allow some non-specific interaction between less than perfectly matched sequences to occur as well.
- the nucleic acids can be "washed” under moderate or high conditions of stringency to dissociate duplexes that are bound together by some non-specific interaction (the nucleic acids that form these duplexes are thus not completely complementary) .
- the optimal conditions for washing are determined empirically, often by gradually increasing the stringency.
- the parameters that can be changed to affect stringency include, primarily, temperature and salt concentration. In general, the lower the salt concentration and the higher the temperature, the higher the stringency. Washing can be initiated at a low temperature (for example, room temperature) using a solution containing a salt concentration that is equivalent to or lower than that of the hybridization solution. Subsequent washing can be carried out using progressively warmer solutions having the same salt concentration. As alternatives, the salt concentration can be lowered and the temperature maintained in the washing step, or the salt concentration can be lowered and the temperature increased. Additional parameters can also be altered. For example, use of a destabilizing agent, such as formamide, alters the stringency conditions.
- nucleic acids In reactions where nucleic acids are hybridized, the conditions used to achieve a given level of stringency will vary. There is not one set of conditions, for example, that will allow duplexes to form between all nucleic acids that are 85% identical to one another; hybridization also depends on unique features of each nucleic acid.
- the length of the sequence, the composition of the sequence (for example, the content of purine-like nucleotides versus the content of pyrimidine- like nucleotides) and the type of nucleic acid (for example, DNA or RNA) affect hybridization.
- An additional consideration is whether one of the nucleic acids is immobilized (for example, on a filter) .
- An example of a progression from lower to higher stringency conditions is the following, where the salt content is given as the relative abundance of SSC (a salt solution containing sodium chloride and sodium citrate; 2X SSC is 10-fold more concentrated than 0.2X SSC).
- Nucleic acids are hybridized at 42°C in 2X SSC/0.1% SDS (sodium dodecylsulfate; a detergent) and then washed in 0.2X SSC/0.1% SDS at room temperature (for conditions of low stringency); 0.2X SSC/0.1% SDS at 42°C (for conditions of moderate stringency); and 0. IX SSC at 68°C (for conditions of high stringency) .
- Washing can be carried out using only one of the conditions given, or each of the conditions can be used (for example, washing for 10-15 minutes each in the order listed above. Any or all of the washes can be repeated. As mentioned above, optimal conditions will vary and can be determined empirically.
- a second set of conditions that are considered "stringent conditions" are those in which hybridization is carried out at 50°C in Church buffer (7% SDS, 0.5% NaHP0 4 , 1 M EDTA, 1% BSA) and washing is carried out at 50°C in 2X SSC. Once detected, the nucleic acid molecules can be isolated by any of a number of standard techniques (see, for example, Sambrook et al . , "Molecular Cloning, A Laboratory Manual," 2nd Ed.
- the invention also encompasses: (a) expression vectors that contain any of the foregoing Tango-67- related coding sequences and/or their complements (that is, "antisense” sequence); (b) expression vectors that contain any of the foregoing Tango- 67 -related coding sequences operatively associated with a regulatory element (examples of which are given below) that directs the expression of the coding sequences; (c) expression vectors containing, in addition to sequences encoding a Tango- 67 polypeptide, nucleic acid sequences that are unrelated to nucleic acid sequences encoding Tango- 67, such as molecules encoding a reporter or marker; and (d) genetically engineered host cells that contain any of the foregoing expression vectors and thereby express the nucleic acid molecules of the invention in the host cell.
- Recombinant nucleic acid molecule can contain a sequence encoding a soluble Tango- 67 polypeptide, mature Tango- 67, Tango- 67 having a signal sequence, or the chemokine-like domain of Tango-67.
- the full length Tango-67 polypeptide, a domain of Tango-67, or a fragment thereof may be fused to additional polypeptides, as described below.
- the nucleic acid molecules of the invention can encode the mature form of Tango-67 or a form that encodes a polypeptide which facilitates secretion.
- the polypeptide is typically referred to as a proprotein, which can be converted into an active form by removal of the signal sequence, for example, within the host cell. Proproteins can be converted into the active form of the protein by removal of the inactivating sequence.
- the regulatory elements referred to above include, but are not limited to, inducible and non-inducible promoters, enhancers, operators and other elements, which are known to those skilled in the art, and which drive or otherwise regulate gene expression.
- Such regulatory elements include but are not limited to the cytomegalovirus hCMV immediate early gene, the early or late promoters of SV40 adenovirus, the lac system, the trp system, the TAC system, the TRC system, the major operator and promoter regions of phage A, the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase, the promoters of acid phosphatase, and the promoters of the yeast ⁇ -mating factors .
- the nucleic acid can form part of a hybrid gene encoding additional polypeptide sequences, for example, sequences that function as a marker or reporter.
- marker or reporter genes include j ⁇ -lactamase, chloramphenicol acetyltransferase (CAT) , adenosine deaminase (ADA) , aminoglycoside phosphotransferase (neo r , G418 r ) , dihydrofolate reductase (DHFR) , hygromycin-B-phosphotransferase (HPH) , thymidine kinase (TK) , lacZ (encoding 3-galactosidase) , and xanthine guanine phosphoribosyltransferase (XGPRT) .
- CAT chloramphenicol acetyltransferase
- ADA adenosine deaminase
- the hybrid polypeptide will include a first portion and a second portion; the first portion being a Tango- 67 polypeptide and the second portion being, for example, the reporter described above or an immunoglobulin constant region.
- the expression systems that may be used for purposes of the invention include, but are not limited to, microorganisms such as bacteria (for example, E. coli and B . subtilis) transformed with recombinant bacteriophage DNA, plasmid DNA, or cosmid DNA expression vectors containing the nucleic acid molecules of the invention; yeast (for example, Saccharoniyces and Pichia) transformed with recombinant yeast expression vectors containing the nucleic acid molecules of the invention (preferably containing the nucleic acid sequence encoding Tango-67 (contained within SEQ ID NO:l)); insect cell systems infected with recombinant virus expression vectors (for example, baculovirus) containing the nucleic acid molecules of the invention; plant cell systems infected with recombinant virus expression vectors (for example, cauliflower mosaic virus (CaMV) and tobacco mosaic virus (TMV) ) or transformed with recombinant plasmid expression vectors (for example, Ti plasmid) containing Tango
- a number of expression vectors may be advantageously selected depending upon the use intended for the gene product being expressed. For example, when a large quantity of such a protein is to be produced, for the generation of pharmaceutical compositions containing Tango-67 polypeptides or for raising antibodies to those polypeptides, vectors that are capable of directing the expression of high levels of fusion protein products that are readily purified may be desirable.
- Such vectors include, but are not limited to, the E. coli expression vector pUR278 (Ruther et al . , EMBO J.
- pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST) .
- fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione.
- the pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.
- Autographa calif omica nuclear polyhidrosis virus can be used as a vector to express foreign genes.
- the virus grows in Spodoptera frugiperda cells.
- the coding sequence of the insert may be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter) .
- Successful insertion of the coding sequence will result in inactivation of the polyhedrin gene and production of non-occluded recombinant virus (i.e., virus lacking the proteinaceous coat coded for by the polyhedrin gene) .
- a number of viral -based expression systems may be utilized.
- the nucleic acid molecule of the invention may be ligated to an adenovirus transcription/translation control complex, for example, the late promoter and tripartite leader sequence.
- This chimeric gene may then be inserted in the adenovirus genome by in vi tro or in vivo recombination. Insertion in a non-essential region of the viral genome (for example, region El or E3) will result in a recombinant virus that is viable and capable of expressing a Tango- 67 gene product in infected hosts (for example, see Logan and Shenk, Proc .
- Specific initiation signals may also be required for efficient translation of inserted nucleic acid molecules . These signals include the ATG initiation codon and adjacent sequences. In cases where an entire gene or cDNA, including its own initiation codon and adjacent sequences, is inserted into the appropriate expression vector, no additional translational control signals may be needed. However, in cases where only a portion of the coding sequence is inserted, exogenous translational control signals, including, perhaps, the ATG initiation codon, must be provided. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert.
- exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic.
- the efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (see Bittner et al . , Methods in Enzymol . 153:516-544, 1987).
- a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (for example, glycosylation) and processing (for example, cleavage) of protein products may be important for the function of the protein.
- Different host cells have characteristic and specific mechanisms for the post- translational processing and modification of proteins and gene products.
- Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed.
- eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used.
- the mammalian cell types listed above are among those that could serve as suitable host cells.
- cell lines which stably express the Tango-67 sequences described above may be engineered.
- host ceils can be transformed with DNA controlled by appropriate expression control elements (for example, promoter, enhancer sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker.
- engineered cells may be allowed to grow for 1-2 days in an enriched media, and then switched to a selective media.
- the selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines.
- This method can advantageously be used to engineer cell lines which express Tango-67.
- Such engineered cell lines may be particularly useful in screening and evaluation of compounds that affect the endogenous activity of the gene product .
- a number of selection systems can be used. For example, the herpes simplex virus thymidine kinase (Wigler, et al .
- genes can be employed in tk “ , hgprt " or aprt " cells, respectively.
- anti-metabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler et al., Proc . Natl . Acad . Sci . USA 77:3567, 1980; O'Hare et al., Proc . Natl . Acad . Sci . USA 78:1527, 1981); gpt, which confers resistance to mycophenolic acid (Mulligan and Berg, Proc . Na tl . Acad . Sci .
- any fusion protein may be readily purified by utilizing an antibody specific for the fusion protein being expressed.
- a system described by Janknecht et al allows for the ready purification of non-denatured fusion proteins expressed in human cell lines ⁇ Proc . Natl . Acad . Sci . USA 88: 8972-8976, 1991).
- the gene of interest is subcloned into a vaccinia recombination plasmid such that the gene's open reading frame is translationally fused to an amino- terminal tag consisting of six histidine residues. Extracts from cells infected with recombinant vaccinia virus are loaded onto Ni 2+ ⁇ nitriloacetic acid-agarose columns and histidine-tagged proteins are selectively eluted with imidazole-containing buffers.
- Tango-67 nucleic acid molecules are useful for diagnosis of disorders associated with aberrant expression of Tango-67.
- Tango-67 nucleic acid molecules are useful in genetic mapping.
- the Tango- 67 polypeptides described herein are those encoded by any of the nucleic acid molecules described above and include Tango-67 fragments, mutants, truncated forms, and fusion proteins. These polypeptides can be prepared for a variety of uses, including but not limited to the generation of antibodies, as reagents in diagnostic assays, for the identification of other cellular gene products or compounds that can modulate the activity or expression of Tango- 67, and as pharmaceutical reagents useful for the treatment of disorders associated with aberrant expression or activity of Tango-67.
- Preferred polypeptides are substantially pure Tango- 67 polypeptides, including those that correspond to the polypeptide with an intact signal sequence, the secreted form of the polypeptide of the human Tango- 67 polypeptide. Especially preferred are polypeptides that are soluble under normal physiological conditions.
- the invention also encompasses polypeptides that are functionally equivalent to Tango-67. These polypeptides are equivalent to Tango- 67 m that they are capable of carrying out one or more of the functions of Tango-67 m a biological system.
- Preferred Tango-67 polypeptides have 20%, 40%, 50%, 75%, 80%, or even 90% of the activity of the full-length, mature human form of Tango- 67.
- Such comparisons are generally based on an assay of biological activity m which equal concentrations of the polypeptides are used and compared. The comparison can also be based on the amount of the polypeptide required to reach 50% of the maximal stimulation obtainable.
- Functionally equivalent proteins can be those, for example, that contain additional or substituted ammo acid residues. Substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved. Ammo acids that are typically considered to provide a conservative substitution for one another are specified m the summary of the invention.
- Polypeptides that are functionally equivalent to Tango- 67 can be made using random mutagenesis techniques well known to those skilled the art (and the resulting mutant Tango- 67 proteins can be tested for activity) . It is more likely, however, that such polypeptides will be generated by site-directed mutagenesis (again using techniques well known to those skilled m the art) . These polypeptides may have an increased function, i . e . , a greater ability to inhibit cellular proliferation, or to evoke an inflammatory response. Such polypeptides can be used to protect progenitor cells from the effects of chemotherapy and/or radiation therapy. To design functionally equivalent polypeptides, it is useful to distinguish between conserved positions and variable positions.
- Tango- 67 coding sequence can be made to generate Tango- 67s that are better suited for expression in a selected host cell.
- N- linked glycosylation sites can be altered or eliminated to achieve, for example, expression of a homogeneous product that is more easily recovered and purified from yeast hosts which are known to hyperglycosylate N-linked sites.
- polypeptides of the invention can be expressed fused to another polypeptide, for example, a marker polypeptide or fusion partner.
- the polypeptide can be fused to a hexa-histidine tag to facilitate purification of bacterially expressed protein or a hemagglutinin tag to facilitate purification of protein expressed in eukaryotic cells.
- polypeptides of the invention can be chemically synthesized (for example, see Creighton, "Proteins: Structures and Molecular Principles,” W.H. Freeman & Co., NY, 1983), or, perhaps more advantageously, produced by recombinant DNA technology as described herein.
- skilled artisans may consult Ausubel et al . ( supra) , Sambrook et al . ("Molecular Cloning, A Laboratory Manual,” Cold Spring Harbor Press, Cold Spring Harbor, NY, 1989), and, particularly for examples of chemical synthesis Gait, M.J. Ed. ("Oligonucleotide Synthesis," IRL Press, Oxford, 1984) .
- the invention also features polypeptides that interact with Tango-67 (and the genes that encode them) and thereby alter the function of Tango-67.
- Interacting polypeptides can be identified using methods known to those skilled in the art.
- One suitable method is the "two-hybrid system," which detects protein interactions in vivo (Chien et al . , Proc . Na tl . Acad . Sci . USA, 88:9578, 1991) .
- a kit for practicing this method is available from Clontech (Palo Alto, CA) .
- Tango- 67 polypeptides are useful for growth promotion. Accordingly they have applications in wound healing, tissue repair, implant fixation, and stimulation of bone growth.
- Tango- 67 polypeptides can also be expressed in transgenic animals. These animals represent a model system for the study of disorders that are caused by or exacerbated by overexpression or underexpression of Tango- 67, and for the development of therapeutic agents that modulate the expression or activity of Tango-67.
- Transgenic animals can be farm animals (pigs, goats, sheep, cows, horses, rabbits, and the like) rodents (such as rats, guinea pigs, and mice), non-human primates (for example, baboons, monkeys, and chimpanzees), and domestic animals (for example, dogs and cats) . Transgenic mice are especially preferred.
- any technique known m the art can be used to introduce a Tango- 67 transgene into animals to produce the founder lines of transgenic animals.
- Such techniques include, but are not limited to, pronuclear micromiection (U.S. Pat. No. 4,873,191); retrovirus mediated gene transfer into germ lines (Van der Putten et al . , Proc . Natl . Acad . Sci . , USA 82:6148, 1985); gene targeting into embryonic stem cells (Thompson et al . , Cell 56:313, 1989); and electroporation of embryos (Lo, Mol . Cell . Biol . 3:1803, 1983).
- the present invention provides for transgenic animals that carry the Tango- 67 transgene m all their cells, as well as animals that carry the transgene in some, but not all of their cells. That is, the invention provides for mosaic animals.
- the transgene can be integrated as a single transgene or in concatamers, e.g., head-to-head tandems or head-to-tail tandems.
- the transgene can also be selectively introduced into and activated a particular cell type (Lasko et al . , Proc . Natl . Acad . Sci . USA 89:6232, 1992).
- the regulatory sequences required for such a cell -type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art .
- Tango- 67 transgene When it is desired that the Tango- 67 transgene be integrated into the chromosomal site of the endogenous Tango-67 gene, gene targeting is preferred. Briefly, when such a technique is to be used, vectors containing some nucleotide sequences homologous to an endogenous Tango- 67 gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous gene. The transgene also can be selectively introduced into a particular cell type, thus inactivating the endogenous Tango-67 gene in only that cell type (Gu et al . , Science 265:103, 1984) . The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. These techniques are useful for preparing "knock outs" having no functional Tango- 67 gene.
- the expression of the recombinant Tango- 67 gene can be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to determine whether integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, in si tu hybridization analysis, and RT-PCR. Samples of Tango- 67 gene- expressing tissue can also be evaluated immunocytochemically using antibodies specific for the Tango-67 transgene product.
- Human Tango- 67 polypeptides can be used to raise antibodies useful m the invention; such polypeptides can be produced by recombinant techniques or synthesized (see, for example, "Solid Phase Peptide Synthesis," supra ; Ausubel et al . , supra)
- the peptides can be coupled to a carrier protein, such as KLH, as described m Ausubel et al . , supra , mixed with an adjuvant, and injected into a host mammal.
- Antibodies can be purified by peptide antigen affinity chromatography.
- various host animals can be immunized by injection with a Tango-67 protein or polypeptide.
- Host animals include rabbits, mice, guinea pigs, and rats.
- Various adjuvants that can be used to increase the immunological response depend on the host species and include Freund's adjuvant (complete and incomplete) , mineral gels such as aluminum hydroxide, surface active substances such as lysolecithm, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanm, and dmitrophenol .
- BCG Bacille Calmette-Guerm
- Polyclonal antibodies are heterogeneous populations of antibody molecules that are contained m the sera of the immunized animals.
- Antibodies withm the invention therefore include polyclonal antibodies and, m addition, monoclonal antibodies, humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab') 2 fragments, and molecules produced using a Fab expression library.
- Monoclonal antibodies which are homogeneous populations of antibodies to a particular antigen, can be prepared using the Tango- 67 proteins described above and standard hyb ⁇ doma technology (see, for example, Kohler et al., Na ture 256:495, 1975; Kohler et al . , Eur. J. Immunol . 6:511, 1976; Kohler et al . , Eur. J. Immunol . 6:292, 1976; Hammerling et al . , "Monoclonal Antibodies and T Cell Hybridomas," Elsevier, NY, 1981; Ausubel et al . , supra) .
- monoclonal antibodies can be obtained by any technique that provides for the production of antibody molecules by continuous cell lines in culture such as described in Kohler et al . , Nature 256:495, 1975, and U.S. Patent No. 4,376,110; the human B-cell hybridoma technique (Kosbor et al . , Immunology
- Such antibodies can be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD and any subclass thereof .
- the hybridoma producing the mAb of this invention may be cultivated in vi tro or in vivo . The ability to produce high titers of mAbs in vivo makes this the presently preferred method of production.
- polyclonal or monoclonal antibodies are tested for specific Tango-67 recognition by Western blot or immunoprecipitation analysis by standard methods, e.g., as described in Ausubel et al . , supra .
- Antibodies that specifically recognize and bind to Tango-67 are useful in the invention.
- such antibodies can be used in an immunoassay to monitor the level of Tango- 67 produced by a mammal (for example, to determine the amount or subcellular location of Tango- 67) .
- antibodies of the invention are produced using fragments of the Tango-67 protein which lie outside highly conserved regions and appear likely to be antigenic, by criteria such as high frequency of charged residues.
- such fragments are generated by standard techniques of PCR, and are then cloned into the pGEX expression vector (Ausubel et al . , supra) . Fusion proteins are expressed in E. coli and purified using a glutathione agarose affinity matrix as described in Ausubel, et al . , supra . In some cases it may be desirable to minimize the potential problems of low affinity or specificity of antisera. In such circumstances, two or three fusions can be generated for each protein, and each fusion can be injected into at least two rabbits. Antisera can be raised by injections in a series, preferably including at least three booster injections.
- Antisera is also checked for its ability to immunoprecipitate recombinant Tango-67 proteins or control proteins, such as glucocorticoid receptor, CAT, or luciferase.
- the antibodies can be used, for example, in the detection of the Tango- 67 in a biological sample as part of a diagnostic assay. Antibodies also can be used in a screening assay to measure the effect of a candidate compound on expression or localization of Tango-67.
- Such antibodies can be used in conjunction with the gene therapy techniques described to, for example, evaluate the normal and/or engineered Tango-67- expressing cells prior to their introduction into the patient. Such antibodies additionally can be used in a method for inhibiting abnormal Tango-67 activity.
- techniques developed for the production of "chimeric antibodies" (Morrison et al . , Proc . Natl . Acad . Sci . USA , 81:6851, 1984; Neuberger et al . , Nature, 312:604, 1984; Takeda et al .
- a chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region.
- Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide.
- Antibody fragments that recognize and bind to specific epitopes can be generated by known techniques.
- such fragments include but are not limited to F(ab') 2 fragments that can be produced by pepsin digestion of the antibody molecule, and Fab fragments that can be generated by reducing the disulfide bridges of F(ab') 2 fragments.
- Fab expression libraries can be constructed (Huse et al . , Science, 246:1275, 1989) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity.
- Antibodies to Tango- 67 can, in turn, be used to generate anti-idiotype antibodies that resemble a portion of Tango-67 using techniques well known to those skilled in the art (see, e.g., Greenspan et al . , FASEB J. 7:437, 1993; Nissinoff, J. Immunol . 147:2429, 1991).
- antibodies that bind to Tango- 67 and competitively inhibit the binding of a ligand of Tango- 67 can be used to generate anti-idiotypes that resemble a ligand binding domain of Tango-67 and, therefore, bind and neutralize a ligand of Tango-67.
- Antibodies can be humanized by methods known in the art. For example, monoclonal antibodies with a desired binding specificity can be commercially humanized (Scotgene, Scotland; Oxford Molecular, Palo Alto, CA) . Fully human antibodies, such as those expressed in transgenic animals are also features of the invention (Green et al . , Nature Genetics 7:13-21, 1994; see also U.S. Patents 5,545,806 and 5,569,825, both of which are hereby incorporated by reference) .
- anti-Tango- 67 antibodies may be employed, for example, by utilizing pre-packaged diagnostic kits comprising at least one specific Tango-67 nucleotide sequence or antibody reagent described herein, which may be conveniently used, for example, in clinical settings, to diagnose patients exhibiting symptoms of the disorders described below.
- Treatment regimes based on an "antisense” approach involve the design of oligonucleotides (either DNA or RNA) that are complementary to Tango- 67 mRNA. These oligonucleotides bind to the complementary Tango-67 mRNA transcripts and prevent translation. Absolute complementarity, although preferred, is not required.
- a sequence "complementary" to a portion of an RNA, as referred to herein, means a sequence having sufficient complementarily to be able to hybridize with the RNA, forming a stable duplex; in the case of double-stranded antisense nucleic acids, a single strand of the duplex DNA may be tested, or triplex formation may be assayed.
- the ability to hybridize will depend on both the degree of complementarily and the length of the antisense nucleic acid. Generally, the longer the hybridizing nucleic acid, the more base mismatches with an RNA it may contain and still form a stable duplex (or triplex, as the case may be) . One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.
- Oligonucleotides that are complementary to the 5' end of the message should work most efficiently at inhibiting translation.
- sequences complementary to the 3' untranslated sequences of mRNAs recently have been shown to be effective at inhibiting translation of mRNAs as well (Wagner, Na ture 372:333, 1984) .
- oligonucleotides complementary to either the 5' or 3' non-translated, non-coding regions of the Tango-67 gene e.g., the human gene shown in the Figure could be used in an antisense approach to inhibit translation of endogenous Tango- 67 mRNA.
- Oligonucleotides complementary to the 5' untranslated region of the mRNA should include the complement of the AUG start codon.
- Antisense oligonucleotides complementary to mRNA coding regions are less efficient inhibitors of translation but could be used in accordance with the invention. Whether designed to hybridize to the 5', 3', or coding region of Tango-67 mRNA, antisense nucleic acids should be at least six nucleotides in length, and are preferably oligonucleotides ranging from 6 to about 50 nucleotides in length. In specific aspects the oligonucleotide is at least 10 nucleotides, at least 17 nucleotides, at least 25 nucleotides, or at least 50 nucleotides.
- vi tro studies are first performed to quantitate the ability of the antisense oligonucleotide to inhibit gene expression. It is preferred that these studies utilize controls that distinguish between antisense gene inhibition and nonspecific biological effects of oligonucleotides. It is also preferred that these studies compare levels of the target RNA or protein with that of an internal control RNA or protein. Additionally, it is envisioned that results obtained using the antisense oligonucleotide are compared with those obtained using a control oligonucleotide.
- control oligonucleotide is of approximately the same length as the test oligonucleotide and that the nucleotide sequence of the oligonucleotide differs from the antisense sequence no more than is necessary to prevent specific hybridization to the target sequence .
- the oligonucleotides can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded.
- the oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule, hybridization, etc.
- the oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo) , or agents facilitating transport across the cell membrane (as described, e.g., in Letsinger et al . , Proc . Natl . Acad . Sci . USA 86:6553, 1989; Lemaitre et al .
- the oligonucleotide can be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking age ⁇ _ , transport agent, or hybridization-triggered cleavage agent.
- the antisense oligonucleotide may comprise at least one modified base moiety which is selected from the group including, but not limited to, 5-fluorouracil , 5-bromouracil , 5-chlorouracil , 5-iodouracil , hypoxanthine, xantine, 4-acetylcytosine, 5- (carboxyhydroxylmethyl) uracil, 5- carboxymethylaminomethyl-2-thiouridine, 5-carboxymethyl- aminomethyluracil , dihydrouracil , beta-D- galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2 , 2-dimethylguanine, 2-methyladenine, 2 -methylguanine, 3 -methylcytosine, 5 -methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil , 5-methoxyaminomethyl- 2-thi
- 2-thiocytosine 5-methyl-2-theouracil , 2 -thiouracil , 4- thiouracil, 5-methyluracil , uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v) , 5-methyl- 2-thiouracil , 2- (3-amino-3-N-2 -carboxypropl) uracil, (acp3)w, and 2 , 6-diaminopurine .
- the antisense oligonucleotide may also comprise at least one modified sugar moiety selected from the group including, but not limited to, arabinose, 2-fluoroarabinose, xylulose, and hexose .
- the antisense oligonucleotide comprises at least one modified phosphate backbone selected from the group consisting of a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal, or an analog of any of these backbones.
- the antisense oligonucleotide is an ⁇ -anomeric oligonucleotide.
- An o.-anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual j ⁇ -units, the strands run parallel to each other (Gautier et al . , Nucl . Acids . Res . 15:6625, 1987).
- the oligonucleotide is a 2 ' -O-methylribonucleotide (Inoue et al . , Nucl . Acids Res . 15:6131, 1987), or a chimeric RNA-DNA analog (Inoue et al . , FEBS Lett . 215:327, 1987).
- Antisense oligonucleotides of the invention can be synthesized by standard methods known in the art, e.g., by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.).
- an automated DNA synthesizer such as are commercially available from Biosearch, Applied Biosystems, etc.
- phosphorothioate oligonucleotides can be synthesized by the method of Stein et al . (Nucl . Acids Res . 16:3209, 1988)
- methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin et al . , Proc . Natl . Acad . Sci . USA 85:7448, 1988) .
- antisense nucleotides complementary to the Tango-67 coding region sequence could be used, those complementary to the transcribed untranslated region are most preferred.
- the antisense molecules should be delivered to cells that express Tango-67 in vivo, e.g., cells of the heart, skeletal muscle, thymus, spleen, and small intestine.
- a number of methods have been developed for delivering antisense DNA or RNA to cells; e.g., antisense molecules can be injected directly into the tissue site, or modified antisense molecules, designed to target the desired cells (e.g., antisense linked to peptides or antibodies that specifically bind receptors or antigens expressed on the target cell surface) can be administered systemically.
- a preferred approach uses a recombinant DNA construct in which the antisense oligonucleotide is placed under the control of a strong pol III or pol II promoter.
- the use of such a construct to transfect target cells in the patient will result in the transcription of sufficient amounts of single stranded RNAs that will form complementary base pairs with the endogenous Tango- 67 transcripts and thereby prevent translation of the Tango- 67 mRNA.
- a vector can be introduced in vivo such that it is taken up by a cell and directs the transcription of an antisense RNA. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA.
- Vectors can be constructed by recombinant DNA technology methods standard in the art .
- Vectors can be plasmid, viral, or others known in the art, used for replication and expression in mammalian cells.
- Expression of the sequence encoding the antisense RNA can be by any promoter known in the art to act in mammalian, preferably human cells.
- Such promoters can be inducible or constitutive.
- Such promoters include, but are not limited to: the SV40 early promoter region (Bernoist et al . , Nature 290:304, 1981); the promoter contained in the 3 ' long terminal repeat of Rous sarcoma virus (Yamamoto et al .
- Ribozyme molecules designed to catalytically cleave Tango- 67 mRNA transcripts also can be used to prevent translation of Tango- 67 mRNA and expression of Tango-67 (see, e.g., PCT Publication WO 90/11364; Saraver et al . , Science 247:1222, 1990). While various ribozymes that cleave mRNA at site-specific recognition sequences can be used to destroy Tango- 67 mRNAs, the use of hammerhead ribozymes is preferred. Hammerhead ribozymes cleave mRNAs at locations dictated by flanking regions that form complementary base pairs with the target mRNA.
- the target mRNA have the following sequence of two bases: 5'-UG-3'.
- the construction and production of hammerhead ribozymes is well known in the art (Haseloff et al . , Na ture 334:585, 1988) .
- the ribozyme is engineered so that the cleavage recognition site is located near the 5' end of the Tango-67 mRNA, i.e., to increase efficiency and minimize the intracellular accumulation of non-functional mRNA transcripts .
- the ribozymes of the present invention also include RNA endoribonucleases (hereinafter "Cech-type ribozymes”), such as the one that occurs naturally in Tet-ra y_ ⁇ .e-ia Thermophila (known as the IVS or L-19 IVS RNA) , and which has been extensively described by Cech and his collaborators (Zaug et al . , Sci ence 224:574, 1984; Zaug et al . , Sci ence, 231:470, 1986; Switzerland et al . , Nature 324:429, 1986; PCT Application No. WO 88/04300; and Been et al . , Cell 47:207, 1986).
- Cech-type ribozymes such as the one that occurs naturally in Tet-ra y_ ⁇ .e-ia Thermophila (known as the IVS or L-19 IVS RNA) , and which has been extensively described by Cech and his collaborators (Z
- the Cech-type ribozymes have an eight base-pair sequence that hybridizes to a target RNA sequence, whereafter cleavage of the target RNA takes place.
- the invention encompasses those Cech-type ribozymes that target eight base-pair active site sequences present in Tango-67.
- the ribozymes can be composed of modified oligonucleotides (e.g., for improved stability, targeting, etc.), and should be delivered to cells which express the Tango-67 in vi vo, e.g., heart, skeletal muscle, thymus, spleen, and small intestine.
- a preferred method of delivery involves using a DNA construct "encoding" the ribozyme under the control of a strong constitutive pol III or pol II promoter, so that transfected cells will produce sufficient quantities of the ribozyme to destroy endogenous Tango-67 messages and inhibit translation. Because ribozymes, unlike antisense molecules, are catalytic, a lower intracellular concentration is required for efficiency.
- Such approaches are particularly suited for use in the agricultural field where modifications to ES (embryonic stem) cells can be used to generate animal offspring with an inactive Tango- 67.
- this approach can be adapted for use in humans, provided the recombinant DNA constructs are directly administered or targeted to the required site in vivo using appropriate viral vectors.
- endogenous Tango- 67 gene expression can be reduced by targeting deoxyribonucleotide sequences complementary to the regulatory region of the Tango-67 gene (i.e., the Tango-67 promoter and/or enhancers) to form triple helical structures that prevent transcription of the Tango- 67 gene in target cells in the body (Helene Anticancer Drug Res . 6:569, 1981; Helene et al . , Ann . N. Y. Acad . Sci . 660:27, 1992; and Maher, Bioassays 14:807, 1992) .
- deoxyribonucleotide sequences complementary to the regulatory region of the Tango-67 gene i.e., the Tango-67 promoter and/or enhancers
- Tango-67 function e.g., to recruit immune cells that will resolve the primary infection or mediate an anti-tumor response.
- the invention also features polypeptides which interact with Tango- 67.
- Any method suitable for detecting protein-protein interactions may be employed for identifying transmembrane proteins, intracellular, or extracellular proteins that interact with Tango-67.
- traditional methods which may be employed are co-immunoprecipitation, crosslinking and co-purification through gradients or chromatographic columns of cell lysates or proteins obtained from cell lysates and the use of Tango-67 to identify proteins in the lysate that interact with Tango-67.
- the Tango-67 polypetide can be a full length Tango-67, a soluble extracellular domain of Tango- 67, or some other suitable Tango- 67 polypeptide.
- an interacting protein can be identified and cloned and then used, in conjunction with standard techniques, to identify proteins with which it interacts.
- at least a portion of the amino acid sequence of a protein which interacts with the Tango-67 can be ascertained using techniques well known to those of skill in the art, such as via the Edman degradation technique.
- the amino acid sequence obtained may be used as a guide for the generation of oligonucleotide mixtures that can be used to screen for gene sequences encoding the interacting protein. Screening may be accomplished, for example, by standard hybridization or PCR techniques. Techniques for the generation of oligonucleotide mixtures and the screening are well-known. (Ausubel, supra ; and "PCR
- methods may be employed which result directly in the identification of genes which encode proteins which interact with Tango-67. These methods include, for example, screening expression libraries, in a manner similar to the well known technique of antibody probing of ⁇ gtll libraries, using labeled Tango-67 polypeptide or a Tango-67 fusion protein, e.g., a Tango- 67 polypeptide or domain fused to a marker such as an enzyme, fluorescent dye, a luminescent protein, or to an IgFc domain.
- a marker such as an enzyme, fluorescent dye, a luminescent protein, or to an IgFc domain.
- a method which detects protein interactions in vivo is the two-hybrid system (Chien et al . , Proc . Na tl . Acad . Sci . USA , 88:9578, 1991) .
- a kit for practicing this method is available from Clontech (Palo Alto, CA) .
- plasmids are constructed that encode two hybrid proteins : one plasmid includes a nucleotide sequence encoding the DNA-binding domain of a transcription activator protein fused to a nucleotide sequence encoding Tango- 67, a Tango- 67 polypeptide, or a Tango- 67 fusion protein, and the other plasmid includes a nucleotide sequence encoding the transcription activator protein's activation domain fused to a cDNA encoding an unknown protein which has been recombined into this plasmid as part of a cDNA library.
- the DNA-binding domain fusion plasmid and the cDNA library are transformed into a strain of the yeast Saccharomyces cerevisiae that contains a reporter gene (e.g., HBS or LacZ) whose regulatory region contains the transcription activator's binding site.
- a reporter gene e.g., HBS or LacZ
- Either hybrid protein alone cannot activate transcription of the reporter gene : the DNA-binding domain hybrid cannot because it does not provide activation function and the activation domain hybrid cannot because it cannot localize to the activator's binding sites. Interaction of the two hybrid proteins reconstitutes the functional activator protein and results in expression of the reporter gene, which is detected by an assay for the reporter gene product .
- the two-hybrid system or related methodology may be used to screen activation domain libraries for proteins that interact with the "bait" gene product.
- Tango-67 may be used as the bait gene product .
- Total genomic or cDNA sequences are fused to the DNA encoding an activation domain.
- This library and a plasmid encoding a hybrid of bait Tango- 67 gene product fused to the DNA- binding domain are cotransformed into a yeast reporter strain, and the resulting transformants are screened for those that express the reporter gene.
- a bait Tango- 67 gene sequence such as Tango-67 or a domain of Tango- 67 can be cloned into a vector such that it is translationally fused to the DNA encoding the DNA-binding domain of the GAL4 protein.
- These colonies are purified and the library plasmids responsible for reporter gene expression are isolated. DNA sequencing is then used to identify the proteins encoded by the library plasmids.
- a cDNA library of the cell line from which proteins that interact with bait Tango- 67 gene product are to be detected can be made using methods routinely practiced in the art.
- the cDNA fragments can be inserted into a vector such that they are translationally fused to the transcriptional activation domain of GAL4.
- This library can be co-transformed along with the bait Tango-67 gene-GAL4 fusion plasmid into a yeast strain which contains a lacZ gene driven by a promoter which contains GAL4 activation sequence.
- a cDNA encoded protein, fused to GAL4 transcriptional activation domain, that interacts with bait Tango- 67 gene product will reconstitute an active GAL4 protein and thereby drive expression of the HIS3 gene.
- Colonies which express HIS3 can then be purified from these strains, and used to produce and isolate the bait Tango-67 gene-interacting protein using techniques routinely practiced in the art.
- a Tango-67 receptor can be identified as follows. First cells or tissues which bind Tango-67 are identified. An expression library is prepared using mRNA isolated from Tango-67 binding cells. The expression library is used to transfect; eulcaryatic cells, e.g., CHO cells. Detectably labelled Tango-67 and, clones which bind Tango- 67 are isolated and purified. The expression plasmid is then isolated from the Tango-67- binding clones. These expression plasmids will encode putaslive Tango-67 receptors. Cells or tissues bearing a Tango-67 receptor can be identified by exposing detectably labelled Tango-67 to various cells lines and tissues.
- a microphysiometer can be used to determine whether a selected cells responds to the presence of a cell receptor ligand (McConnel et al . , Sci ence 257:1906, 1992) .
- Compounds which bind Tango-67 can be identified using any standard binding assay. For example, candidate compounds can be bound to a solid support. Tango-67 is then exposed to the immobilized compound and binding is measured (European Patent Application 84/03564) .
- Toxicity and therapeutic efficacy of the polypeptides of the invention and the compounds that modulate their expression or activity can be determined by standard pharmaceutical procedures, using either cells in culture or experimental animals to determine the LD 50 (the dose lethal to 50% of the population) and the ED 50 (the dose therapeutically effective in 50% of the population) .
- the dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD 50 /ED 50 .
- Polypeptides or other compounds that exhibit large therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.
- the data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans .
- the dosage of such compounds lies preferably within a range of circulating concentrations that include the ED 50 with little or no toxicity.
- the dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
- the therapeutically effective dose can be estimated initially from cell culture assays.
- a dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC 50 (that is, the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture.
- IC 50 that is, the concentration of the test compound which achieves a half-maximal inhibition of symptoms
- levels in plasma may be measured, for example, by high performance liquid chromatography.
- compositions for use in accordance with the present invention may be formulated in conventional manner using one or more physiologically acceptable carriers or excipients.
- the compounds and their physiologically acceptable salts and solvates may be formulated for administration by inhalation or insufflation (either through the mouth or the nose) or oral, buccal, parenteral or rectal administration.
- the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (for example, pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose) ; fillers (for example, lactose, microcrystalline cellulose or calcium hydrogen phosphate) ; lubricants (for example, magnesium stearate, talc or silica); disintegrants (for example, potato starch or sodium starch glycolate) ; or wetting agents (for example, sodium lauryl sulphate) .
- binding agents for example, pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose
- fillers for example, lactose, microcrystalline cellulose or calcium hydrogen phosphate
- lubricants for example, magnesium stearate, talc or silica
- disintegrants for example, potato starch or sodium starch glycolate
- wetting agents for example,
- Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use.
- Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (for example, sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (for example, lecithin or acacia); non-aqueous vehicles (for example, almond oil, oily esters, ethyl alcohol or fractionated vegetable oils) ; and preservatives (for example, methyl or propyl - p-hydroxybenzoates or sorbic acid) .
- the preparations may also contain buffer salts, flavoring, coloring and sweetening agents as appropriate.
- Preparations for oral administration may be suitably formulated to give controlled release of the active compound.
- compositions may take the form of tablets or lozenges formulated in conventional manner.
- the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, for example, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
- a suitable propellant for example, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
- a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount.
- Capsules and cartridges of, for example, gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
- the compounds may be formulated for parenteral administration by injection, for example, by bolus injection or continuous infusion.
- Formulations for injection may be presented in unit dosage form, for example, in ampoules or in multi -dose containers, with an added preservative.
- the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
- the active ingredient may be in powder form for constitution with a suitable vehicle, for example, sterile pyrogen-free water, before use.
- a suitable vehicle for example, sterile pyrogen-free water
- the compounds may also be formulated in rectal compositions such as suppositories or retention enemas, for example, containing conventional suppository bases such as cocoa butter or other glycerides .
- the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
- the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
- compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient.
- the pack may for example comprise metal or plastic foil, such as a blister pack.
- the pack or dispenser device may be accompanied by instructions for administration.
- the therapeutic compositions of the invention can also contain a carrier or excipient, many of which are known to skilled artisans. Excipients which can be used include buffers (for example, citrate buffer, phosphate buffer, acetate buffer, and bicarbonate buffer) , amino acids, urea, alcohols, ascorbic acid, phospholipids, proteins (for example, serum albumin), EDTA, sodium chloride, liposomes, mannitol, sorbitol, and glycerol .
- the nucleic acids, polypeptides, antibodies, or modulatory compounds of the invention can be administered by any standard route of administration.
- administration can be parenteral, intravenous, subcutaneous, intramuscular, intracranial , intraorbital , opthalmic, intraventricular, intracapsular, intraspinal, intracisternal , intraperitoneal , transmucosal , or oral.
- the modulatory compound can be formulated in various ways, according to the corresponding route of administration.
- liquid solutions can be made for ingestion or injection; gels or powders can be made for ingestion, inhalation, or topical application. Methods for making such formulations are well known and can be found in, for example, "Remington's Pharmaceutical Sciences.” It is expected that the preferred route of administration will be intravenous.
- Example 1 describes the identification and sequencing of a human Tango-67 gene.
- Example 2 describes the characterization of Tango-67, particularly the expression pattern.
- Complementary DNA was directionally clones into the expression plasmid pMET7 using the Sail and NotI sites in the polylinker to construct a plasmid library.
- Transformants were picked and grown up for single-pass sequencing.
- astrocyte cDNA was ligated into the Sall/NotI sites of the ZipLox vector (Gibco BRL) for construction of a lambda phage cDNA library.
- Tango 67 encodes a protein of 223 amino acids that is 36% identical to D. melanogaster TSG, based on comparisons using the GAP program from GCG (Madison, WI) .
- Tango 67 was analyzed using Northern blot hybridization.
- a 410 base pair (bp) DNA fragment was generated using PCR (corresponding to nucleotides 234 to 643 in SEQ ID NO:l) for use as a probe.
- the DNA was radioactively labeled with 32 P-dCTP using the Prime-It kit (Strategen, LaJolla, CA) according to the instructions of the supplier.
- Filters containing human mRNA (MTNI and MTNII form Clontech, Palo Alto, CA) were probed in ExpressHyb hybridization solution (Clontech) and washed at high stringency according to using a slight variation of the manufacturer's recommendations.
- the high stringency wash is 2 x 20 min in 2X SSC, 0.05% SDS at 55°C; then 2 x 20 min in 0. IX SSC, 0.1% SDS at 55°C.
- Tango 67 is expressed at variable levels in all tissues examined (spleen, thymus, prostate, testes, ovary, small intestine, colon, PBLs , heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas.)
- the Tango 67 gene is expressed as two transcripts, an -4.4 kilobase (kb) and -2.4 kb mRNA, in good agreement with the cDNA clones isolated.
- the relative levels of the two transcripts vary from tissue to tissue, though with the exception of testes, the 4.4 transcript is significantly more abundant . In the testes the levels of the 4.4 and 2.4 kb mRNAs are approximately the same, and an additional hybridizing transcript is seen at -800 bp .
- a plasmid containing the human full length nucleotide sequence encoding TANGO 67 was deposited with the American type Culture Collection, Rockville, Maryland, on April 16, 1997 and assigned Accession Number 98410.
- the subject culture has been deposited under conditions that assure that access to the culture will be available during the pendency of the patent application to one determined by the Commissioner of Patents and Trademarks to be entitled thereto under 37 CFR 1.14 and 35 USC 122.
- the deposit is available as required by foreign patent laws in countries wherein counterparts of the subject application, or its progeny, are filed. However, it should be understood that the availability of a deposit does not constitute a license to practice the subject invention in derogation of patent rights granted by governmental action.
- the subject culture deposit will be stored and made available to the public in accord with the provisions of the Budapest Treaty for the Deposit of Microorganisms, i.e., it will be stored with all the care necessary to keep it viable and uncontaminated for a period of at least five years after the most recent request for the furnishing of a sample of the deposit, and in any case, for a period of at least 30 (thirty) years after the date of deposit or for the enforceable life of any patent which can issue disclosing the culture plus five years after the last request for a sample from the deposit .
- the depositor acknowledges the duty to replace the deposit should the depository be unable to furnish a sample when requested, due to the condition of the deposit. All restrictions on the availability to the public of the subject culture deposit will be irrevocably removed upon the granting of a patent disclosing them.
Abstract
The invention relates to Tango-67 polypeptides, nucleic acid molecules encoding Tango-67, and uses thereof. Tango-67 is related to a number of growth factors, particularly members of the connective tissue growth factor family.
Description
NOVEL POLYPEPTIDES WITHIN THE GROWTH FACTOR SUPERFA ILY
Background of the Invention The size and differentiated characteristics of cellular compartments are controlled in part by the availability of extracellular growth factors. These growth factors can influence cellular replication, cell survival, as well as the function of differentiated end cells. The ability to control the expansion of specific cell types in vivo has demonstrated clinical utility, the best examples being the stimulation of red and white blood cell production by erythropoietin and granulocyte colony stimulating factor, respectively. The utility of growth factors for the treatment of other human disorders (e.g., neurodegeneration) is currently being examined, and it is hoped that in certain instances providing exogenous growth stimuli may arrest or reverse the course of degenerative disorders, or provide for more rapid restoration of function in cases of acute tissue damage (e.g. wound healing).
Secreted growth factors also play an important role in early development. Although the details of this process are incompletely understood and vary considerably from species to species, genetic analysis in model organisms has demonstrated an important role for growth factors in the differentiation of the early embryo. One such molecule is the product of the twisted gastrulation gene (TSG) , mutations in which lead to defects in embryogenesis . TSG messenger RNA (mRNA) is present in the early embryo and is important for specification of cell fates along the dorsal midline. TSG has been molecularly characterized, and is a cysteine-rich secreted protein that shows homology to connective tissue growth factor (CTGF) . CTGF is itself a mitogen for
fibroblasts and shares antigenic determinants with platelet derived growth factor (PDGF) .
Summary of the Invention The invention relates to the discovery and characterization of Tango-67, a new soluble growth factor. A form of Tango-67 described herein is a 224 amino acid, cysteine rich polypeptide. Northern blot analysis of Tango-67 mRNA reveals that it is present at varying levels in a wide variety of tissues. The invention features an isolated nucleic acid molecule encoding a Tango-67 polypeptide. For example, the isolated nucleic acid molecule encodes the secreted form of human Tango- 67, or a polypeptide having sequence that is at least 85% identical to the sequence of SEQ ID NO : 2. In other embodiments, the isolated nucleic acid molecule claim 1 includes a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 2; and includes the nucleotide sequence of between nucleotide 182 and 850, inclusive, of SEQ ID NO : 1. In other embodiments, the isolated nucleic acid molecule encoding Tango- 67 hybridizes to a nucleic acid molecule having the sequence of nucleotides 182 to 850, inclusive, of SEQ ID NO : 1 or its complement. In other embodiments, the hybridization occurs under stringent conditions.
In other embodiments the isolated nucleic acid molecule encoding Tango- 67 encodes a Tango- 67 polypeptide capable of promoting cell proliferation and/or differentiation. The invention also features a host cell which includes and isolated nucleic acid molecule encoding Tango-67, a nucleic acid vector (e.g., an expression vector, a vector which includes a regulatory element, a vector which includes a regulatory element selected from
the group consisting of the cytomegalovirus hCMV immediate early gene, the early promoter of SV40 adenovirus, the late promoter of SV40 adenovirus, the lac system, the trp system, the TAC system, the TRC system, the major operator and promoter regions of phage λ, the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase, the promoters of acid phosphatase, and the promoters of the yeast α.-mating factors, vector which includes a regulatory element which directs tissue-specific expression, a vector which includes a reporter gene, a vector which includes a reporter gene selected from the group selected from the group consisting of -lactamase, chloramphenicol acetyltransferase (CAT) , adenosine deaminase (ADA) , aminoglycoside phosphotransferase (neor, G418r) , dihydrofolate reductase (DHFR) , hygromycin-B-phosphotransferase (HPH) , thymidine kinase (TK) , lacZ (encoding -galactosidase) , and xanthine guanine phosphoribosyltransferase (XGPRT) , a vector that is a plasmid, a vector that is a virus, a vector that is a retrovirus .
In another embodiment, the invention features a substantially pure Tango-67 polypeptide (e.g., a Tango-67 polypeptide that is soluble under physiological conditions, a Tango- 67 polypeptide which includes a signal sequence, a Tango-67 polypeptide that stimulated proliferation and/or differentiation of a cell, a Tango- 67 polypeptide that includes an amino acid sequence that is at least 85% identical to the amino acid sequence of SEQ ID NO: 2, a Tango-67 polypeptide that includes an amino acid sequence that is at least 90% identical to the amino acid sequence of of SEQ ID NO : 2 , a Tango- 67 polypeptide that includes an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 2, and a Tango- 67 polypeptide that includes an
amino acid sequence that is identical to the amino acid sequence of SEQ ID NO: 2.
In other embodiments, the invention features a substantially pure polypeptide which includes a first portion and a second portion, the first portion including a Tango-67 polypeptide and the second portion including a detectable marker.
The invention also features an antibody that selectively binds to a Tango-67 polypeptide (e.g., a monoclonal antibody) .
The invention also features a pharmaceutical composition which includes a Tango-67 polypeptide.
Also included in the invention are: a method for detecting Tango- 67 in a sample, the method including: (a) obtaining a biological sample;
(b) contacting the biological sample with an antibody that specifically binds Tango- 67 under conditions that allow the formation of Tango- 67 -antibody complexes; and (c) detecting the complexes, if any, as an indication of the presence of Tango- 67 in the sample.
In another aspect, the invention features a method of identifying a compound that modulates the expression of Tango-67, the method including comparing the level of expression of Tango-67 in a cell in the presence and absence of a selected compound, wherein a difference in the level of expression in the presence and absence of the selected compound indicates that the selected compound modulates the expression of Tango- 67.
In another aspect, the invention features, a method of identifying a compound that modulates the activity of Tango- 67, the method including comparing the level of activity of Tango-67 m a cell m the presence and absence of a selected compound, wherein a difference m the level of activity m the presence and absence of the selected compound indicates that the selected compound modulates the activity of Tango-67.
In another aspect, the invention features a method for treating a patient suffering from a disorder associated with excessive expression or activity of Tango- 67, the method including administering to the patient a compound which inhibits expression or activity of Tango- 67. The invention also features a method for treating a patient suffering from a disorder associated with insufficient expression or activity of Tango-67, the method including administering to the patient a compound which increases expression or activity of Tango-67. The invention also features a method for diagnosing a disorder associated with aberrant expression of Tango- 67, the method including obtaining a biological sample from a patient and measuring Tango- 67 expression m the biological sample, wherein increased or decreased Tango-67 expression m the biological sample compared to a control indicates that the patient suffers from a disorder associated with aberrant expression of Tango-67. In another aspect the invention features a method for diagnosing a disorder associated with aberrant activity of Tango- 67, the method including obtaining a biological sample from a patient and measuring Tango- 67 activity m the biological sample, wherein increased or decreased Tango-67 activity m the biological sample compared to a control indicates that the patient suffers
from a disorder associated with aberrant activity of Tango- 67.
The invention encompasses isolated nucleic acid molecules encoding Tango- 67 or a fragment thereof, vectors containing these nucleic acid molecules, cells harboring recombined DNA encoding Tango- 67, fusion proteins which include Tango- 67, transgenic animals which express Tango- 67, recombinant knock-out animals which fail to express Tango-67. Especially preferred are nucleic acid molecules encoding the polypeptide shown in the Figure (SEQ ID NO: 2) .
The invention encompasses nucleic acids that have a sequence that is substantially identical to a Tango-67 nucleic acid sequence. A nucleic acid which is substantially identical to a given reference nucleic acid molecule is hereby defined as a nucleic acid having a sequence that has at least 85%, preferably 90%, and more preferably 95%, 98%, 99% or more identity to the sequence of the given reference nucleic acid molecule, e.g., the nucleic acid sequence of SEQ ID NO : 1.
A polypeptide which is "substantially identical" to a given reference polypeptide molecule is hereby defined as a polypeptide having a sequence that has at least 85%, preferably 90%, and more preferably 95%, 98%, 99% or more identity to the sequence of the given reference polypeptide sequence, e.g., the polypeptide sequence of SEQ ID NO:2.
The nucleic acid molecules of the invention can be inserted into transcription and/or translation vectors, as described below, which will facilitate expression of the insert. The nucleic acid molecules and the polypeptides they encode can be used directly as diagnostic or therapeutic agents, or (in the case of a polypeptide) can be used to generate antibodies that, in turn, are therapeutically useful. Accordingly,
expression vectors containing the nucleic acid molecules of the invention, cells transfected with these vectors, the polypeptides expressed, and antibodies generated, against either the entire polypeptide or an antigenic fragment thereof, are among the preferred embodiments.
A transfected cell is any cell into which (or into an ancestor of which) has been introduced, by means of recombinant DNA techniques, a nucleic acid encoding a polypeptide of the invention (e.g., a Tango-67 polypeptide) . An isolated nucleic acid molecule is a nucleic acid molecule that is separated from the 5' and 3' coding sequences with which it is immediately contiguous in the naturally occurring genome of an organism. Isolated nucleic acid molecule include nucleic acid molecule which are not naturally occurring, e.g., nucleic acid molecules created by recombinant DNA techniques .
The term "nucleic acid molecule" encompasses both RNA and DNA, including cDNA, genomic DNA, and synthetic (e.g., chemically synthesized) DNA. Where single- stranded, the nucleic acid may be a sense strand or an antisense strand.
The invention also encompasses nucleic acid molecules that hybridize, preferably under stringent conditions, to a nucleic acid molecule encoding a Tango- 67 polypeptide (e.g., a nucleic acid molecule having the sequence shown in SEQ ID NO : 1 or a nucleic acid molecule having the sequence of the Tango- 67 encoding portion of the sequence of SEQ ID N0:1) . Preferably the hybridizing nucleic acid molecule consists of 400, more preferably 200 nucleotides.
Preferred hybridizing nucleic acid molecules have an activity possessed by Tango-67, e.g., the ability to increase proliferation and/or differentiation of cells.
The invention also features substantially pure or isolated Tango-67 polypeptides, including those that correspond to various functional domains of Tango-67, or fragments thereof. The polypeptides of the invention encompass ammo acid sequences that are substantially identical to the ammo acid sequence shown the Figure (SEQ ID NO: 2) .
The polypeptides of the invention can also be chemically synthesized, or they can be purified from tissues which they are naturally expressed, according to standard biochemical methods of purification.
Also included m the invention are "functional polypeptides," which possess one or more of the biological functions or activities of Tango-67. These functions include the ability to bind some or all of the proteins which normally bind to Tango-67. A functional polypeptide is also considered within the scope of the invention if it serves as an antigen for production of antibodies that specifically bind to Tango-67. In many cases, functional polypeptides retain one or more domains present m the naturally-occurring form of the polypeptide .
The functional polypeptides may contain a primary ammo acid sequence that has been modified from those disclosed herein. Preferably these modifications consist of conservative ammo acid substitutions, as described herein.
The terms "protein" and "polypeptide" are used herein to describe any chain of ammo acids, regardless of length or post-translational modification (for example, glycosylation or phosphorylation) Thus, the term "Tango-67 polypeptides" includes full-length, naturally occurring Tango- 67 protein (with or without a signal sequence) , as well a reco bmantly or synthetically produced polypeptide that correspond to a
full-length naturally occurring Tango-67 protein or to particular domains or portions of a naturally occurring protein. The term also encompasses mature Tango- 67 which has an added ammo-terminal methionme (useful for expression in prokaryotic cells) .
The term "purified" as used herein refers to a nucleic acid or peptide that is substantially free of cellular material, viral material, or culture medium when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized.
Polypeptides or other compounds of interest are said to be "substantially pure" when they are within preparations that are at least 60% by weight (dry weight) the compound of interest. Preferably, the preparation is at least 75%, more preferably at least 90%, and most preferably at least 99%, by weight the compound of interest . Purity can be measured by any appropriate standard method, for example, by column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis. A polypeptide or nucleic acid molecule is "substantially identical" to a reference polypeptide or nucleic acid molecule if it has a sequence that is at least 85%, preferably at least 90%, and more preferably at least 95%, 98%, or 99% identical to the sequence of the reference polypeptide or nucleic ac d molecule.
Where a particular polypeptide is said to have a specific percent identity to a reference polypeptide of a defined length, the percent identity is relative to the reference peptide. Thus, a peptide that is 50% identical to a reference polypeptide that is 100 ammo acids long can be a 50 ammo acid polypeptide that is completely identical to a 50 ammo acid long portion of the reference polypeptide. It might also be a 100 ammo acid long polypeptide which is 50% identical to the reference
polypeptide over its entire length. Of course, many other polypeptides will meet the same criteria.
In the case of polypeptide sequences which are less than 100% identical to a reference sequence, the non- identical positions are preferably, but not necessarily, conservative substitutions for the reference sequence. Conservative substitutions typically include substitutions within the following groups: glycine and alanine; valine, isoleucine, and leucine; aspartic acid and glutamic acid; asparagine and glutamine; serine and threonine; lysine and arginine; and phenylalanine and tyrosine .
For polypeptides, the length of the reference polypeptide sequence will generally be at least 16 amino acids, preferably at least 20 amino acids, more preferably at least 25 amino acids, and most preferably 35 amino acids, 50 amino acids, or 100 amino acids. For nucleic acids, the length of the reference nucleic acid sequence will generally be at least 50 nucleotides, preferably at least 60 nucleotides, more preferably at least 75 nucleotides, and most preferably 100 nucleotides or 300 nucleotides.
Sequence identity can be measured using sequence analysis software (for example, the Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, WI 53705) , with the default parameters as specified therein.
The nucleic acid molecules of the invention can be inserted into a vector, as described below, which will facilitate expression of the insert. The nucleic acid molecules and the polypeptides they encode can be used directly as diagnostic or therapeutic agents, or can be used (directly in the case of the polypeptide or indirectly in the case of a nucleic acid molecule) to
generate antibodies that, in turn, are clinically useful as a therapeutic or diagnostic agent. Accordingly, vectors containing the nucleic acid of the invention, cells transfected with these vectors, the polypeptides expressed, and antibodies generated, against either the entire polypeptide or an antigenic fragment thereof, are among the preferred embodiments.
As used herein, the term "transformed cell" means a cell into which (or into an ancestor of which) has been introduced, by means of recombinant DNA techniques, a nucleic acid molecule encoding a polypeptide of the invention.
The invention also features antibodies, e.g., monoclonal, polyclonal, and engineered antibodies, which specifically bind Tango-67. By "specifically binds" is meant an antibody that recognizes and binds to a particular antigen, e.g., the Tango-67 polypeptide of the invention, but which does not substantially recognize or bind to other molecules in a sample, e.g., a biological sample, which includes Tango-67.
The invention also features antagonists and agonists of Tango- 67 that can inhibit or enhance one or more of the functions or activities of Tango-67, respectively. Suitable antagonists can include small molecules (i.e., molecules with a molecular weight below about 500), large molecules (i.e., molecules with a molecular weight above about 500) , antibodies that bind and "neutralize" Tango-67 (as described below) , polypeptides which compete with a native form of Tango- 67 for binding to a protein, e.g., the Tango-67 receptor, and nucleic acid molecules that interfere with transcription of Tango- 67 (for example, antisense nucleic acid molecules and ribozymes) . Agonists of Tango- 67 also include small and large molecules, and antibodies other than "neutralizing" antibodies.
The invention also features molecules which can increase or decrease the expression of Tango-67 (e.g., by influencing transcription or translation) . Small molecules (i.e., molecules with a molecular weight below about 500), large molecules (i.e., molecules with a molecular weight above about 500), and nucleic acid molecules that can be used to inhibit the expression of Tango-67 (for example, antisense and ribozyme molecules) or to enhance their expression (for example, expression constructs that place nucleic acid sequences encoding Tango-67 under the control of a strong promoter system) , and transgenic animals that express a Tango- 67 transgene. In addition, the invention features substantially pure polypeptides that functionally interact with Tango- 67, e.g., a Tango-67 receptor, and the nucleic acid molecules that encode them.
The invention encompasses methods for treating disorders associated with aberrant expression or activity of Tango-67. Thus, the invention includes methods for treating disorders associated with excessive expression or activity of Tango-67. Such methods entail administering a compound which decreases the expression or activity of Tango-67. The invention also includes methods for treating disorders associated with insufficient expression of Tango-67. These methods entail administering a compound which increases the expression or activity of Tango- 67.
The invention also features methods for detecting a Tango- 67 polypeptide. Such methods include: obtaining a biological sample; contacting the sample with an antibody that specifically binds Tango- 67 under conditions which permit specific binding; and detecting any antibody-Tango-67 complexes formed.
In addition, the present invention encompasses methods and compositions for the diagnostic evaluation,
typing, and prognosis of disorders associated with inappropriate expression or activity of Tango-67. For example, the nucleic acid molecules of the invention can be used as diagnostic hybridization probes to detect, for example, inappropriate expression of Tango- 67 or mutations in the Tango- 67 gene. Such methods may be used to classify cells by the level of Tango-67 expression.
Alternatively, the nucleic acid molecules can be used as primers for diagnostic PCR analysis for the identification of gene mutations, allelic variations and regulatory defects in the Tango- 67 gene. The present invention further provides for diagnostic kits for the practice of such methods.
The invention features methods of identifying compounds that modulate the expression or activity of Tango-67 by assessing the expression or activity of Tango- 67 in the presence and absence of a selected compound. A difference in the level of expression or activity of Tango- 67 in the presence and absence of the selected compound indicates that the selected compound is capable of modulating expression or activity or Tango-67. Expression can be assessed either at the level of gene expression (e.g., by measuring mRNA) or protein expression by techniques that are well known to skilled artisans. The activity of Tango-67 can be assessed functionally, i.e., by assaying the ability of the compound to inhibit proliferation of myeloid cells.
The preferred methods and materials are described below in examples which are meant to illustrate, not limit, the invention. Skilled artisans will recognize methods and materials that are similar or equivalent to those described herein, and that can be used in the practice or testing of the present invention.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as
commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are described herein. In addition, the materials, methods, and examples are illustrative only and are not intended to be limiting.
Other features and advantages of the invention will be apparent from the detailed description, and from the claims .
Brief Description of the Drawing The Figure is a depiction of the nucleotide sequence encoding Tango-67 and 3' and 5' non-translated sequence (SEQ ID NO:l) and the amino acid sequence (SEQ ID NO: 2) of Tango- 67.
Detailed Description Tango-67 is a new member of the growth factor superfamily. At the protein sequence level, Tango-67 is related to the product of the drosophila twisted gastrulation gene and human connective tissue growth factor .
Tango-67 Nucleic Acid Molecules
The Tango-67 nucleic acid molecules of the invention can be cDNA, genomic DNA, synthetic DNA, or
RNA, and can be double-stranded or single-stranded (i.e., either a sense or an antisense strand) . Fragments of these molecules are also considered within the scope of the invention, and can be produced, for example, by the polymerase chain reaction (PCR) or generated by treatment with one or more restriction endonucleases . A ribonucleic acid (RNA) molecule can be produced by
in vi tro transcription. Preferably, the nucleic acid molecules encode polypeptides that, regardless of length, are soluble under normal physiological conditions.
The nucleic acid molecules of the invention can contain naturally occurring sequences, or sequences that differ from those that occur naturally, but, due to the degeneracy of the genetic code, encode the same polypeptide (for example, the polypeptide of SEQ ID NO: 2) . In addition, these nucleic acid molecules are not limited to sequences that only encode polypeptides, and thus, can include some or all of the non-coding sequences that lie upstream or downstream from a coding sequence .
The nucleic acid molecules of the invention can be synthesized (for example, by phosphoramidite-based synthesis) or obtained from a biological cell, such as the cell of a mammal. Thus, the nucleic acids can be those of a human, mouse, rat, guinea pig, cow, sheep, horse, pig, rabbit, monkey, dog, or cat. Combinations or modifications of the nucleotides within these types of nucleic acids are also encompassed.
In addition, the isolated nucleic acid molecules of the invention encompass fragments that are not found as such in the natural state. Thus, the invention encompasses recombinant molecules, such as those in which a nucleic acid molecule (for example, an isolated nucleic acid molecule encoding Tango- 67) is incorporated into a vector (for example, a plasmid or viral vector) or into the genome of a heterologous cell (or the genome of a homologous cell, at a position other than the natural chromosomal location) . Recombinant nucleic acid molecules and uses therefor are discussed further below.
In the event the nucleic acid molecules of the invention encode or act as antisense molecules, they can be used for example, to regulate translation of Tango-67.
Techniques associated with detection or regulation of Tango- 67 expression are well known to skilled artisans and can be used to diagnose and/or treat inflammation or disorders associated with cellular proliferation. These nucleic acid molecules are discussed further below in the context of their clinical utility.
The invention also encompasses nucleic acid molecules that hybridize under stringent conditions to a nucleic acid molecule encoding a Tango- 67 polypeptide. The cDNA sequence described herein (SEQ ID NO:l) can be used to identify these nucleic acids, which include, for example, nucleic acids that encode homologous polypeptides in other species, and splice variants of the Tango-67 gene in humans or other mammals. Accordingly, the invention features methods of detecting and isolating these nucleic acid molecules. Using these methods, a sample (for example, a nucleic acid library, such as a cDNA or genomic library) is contacted (or "screened") with a Tango- 67-specific probe (for example, a fragment of SEQ ID NO : 1 that is at least 12 nucleotides long) . The probe will selectively hybridize to nucleic acids encoding related polypeptides (or to complementary sequences thereof) . Because the polypeptide encoded by Tango- 67 is related to other C-C chemokines, the term "selectively hybridize" is used to refer to an event in which a probe binds to nucleic acids encoding Tango- 67 (or to complementary sequences thereof) to a detectably greater extent than to nucleic acids encoding other C-C chemokines (or to complementary sequences thereof) . The probe, which can contain at least 12 (for example, 15, 25, 50, 100, or 200 nucleotides) can be produced using any of several standard methods (see, for example, Ausubel et al., "Current Protocols in Molecular Biology, Vol. I," Green Publishing Associates, Inc., and John Wiley & Sons, Inc., NY, 1989) . For example, the probe
can be generated using PCR amplification methods in which oligonucleotide primers are used to amplify a Tango- 67-specific nucleic acid sequence (for example, a nucleic acid encoding the chemokine-like domain) that can be used as a probe to screen a nucleic acid library, as described in Example 1 below, and thereby detect nucleic acid molecules (within the library) that hybridize to the probe .
One single-stranded nucleic acid is said to hybridize to another if a duplex forms between them. This occurs when one nucleic acid contains a sequence that is the reverse and complement of the other (this same arrangement gives rise to the natural interaction between the sense and antisense strands of DNA in the genome and underlies the configuration of the "double helix") . Complete complementarity between the hybridizing regions is not required in order for a duplex to form; it is only necessary that the number of paired bases is sufficient to maintain the duplex under the hybridization conditions used.
Typically, hybridization conditions are of low to moderate stringency. These conditions favor specific interactions between completely complementary sequences, but allow some non-specific interaction between less than perfectly matched sequences to occur as well. After hybridization, the nucleic acids can be "washed" under moderate or high conditions of stringency to dissociate duplexes that are bound together by some non-specific interaction (the nucleic acids that form these duplexes are thus not completely complementary) .
As is known in the art, the optimal conditions for washing are determined empirically, often by gradually increasing the stringency. The parameters that can be changed to affect stringency include, primarily, temperature and salt concentration. In general, the
lower the salt concentration and the higher the temperature, the higher the stringency. Washing can be initiated at a low temperature (for example, room temperature) using a solution containing a salt concentration that is equivalent to or lower than that of the hybridization solution. Subsequent washing can be carried out using progressively warmer solutions having the same salt concentration. As alternatives, the salt concentration can be lowered and the temperature maintained in the washing step, or the salt concentration can be lowered and the temperature increased. Additional parameters can also be altered. For example, use of a destabilizing agent, such as formamide, alters the stringency conditions. In reactions where nucleic acids are hybridized, the conditions used to achieve a given level of stringency will vary. There is not one set of conditions, for example, that will allow duplexes to form between all nucleic acids that are 85% identical to one another; hybridization also depends on unique features of each nucleic acid. The length of the sequence, the composition of the sequence (for example, the content of purine-like nucleotides versus the content of pyrimidine- like nucleotides) and the type of nucleic acid (for example, DNA or RNA) affect hybridization. An additional consideration is whether one of the nucleic acids is immobilized (for example, on a filter) .
An example of a progression from lower to higher stringency conditions is the following, where the salt content is given as the relative abundance of SSC (a salt solution containing sodium chloride and sodium citrate; 2X SSC is 10-fold more concentrated than 0.2X SSC). Nucleic acids are hybridized at 42°C in 2X SSC/0.1% SDS (sodium dodecylsulfate; a detergent) and then washed in 0.2X SSC/0.1% SDS at room temperature (for conditions of
low stringency); 0.2X SSC/0.1% SDS at 42°C (for conditions of moderate stringency); and 0. IX SSC at 68°C (for conditions of high stringency) . Washing can be carried out using only one of the conditions given, or each of the conditions can be used (for example, washing for 10-15 minutes each in the order listed above. Any or all of the washes can be repeated. As mentioned above, optimal conditions will vary and can be determined empirically. A second set of conditions that are considered "stringent conditions" are those in which hybridization is carried out at 50°C in Church buffer (7% SDS, 0.5% NaHP04, 1 M EDTA, 1% BSA) and washing is carried out at 50°C in 2X SSC. Once detected, the nucleic acid molecules can be isolated by any of a number of standard techniques (see, for example, Sambrook et al . , "Molecular Cloning, A Laboratory Manual," 2nd Ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989) . The invention also encompasses: (a) expression vectors that contain any of the foregoing Tango-67- related coding sequences and/or their complements (that is, "antisense" sequence); (b) expression vectors that contain any of the foregoing Tango- 67 -related coding sequences operatively associated with a regulatory element (examples of which are given below) that directs the expression of the coding sequences; (c) expression vectors containing, in addition to sequences encoding a Tango- 67 polypeptide, nucleic acid sequences that are unrelated to nucleic acid sequences encoding Tango- 67, such as molecules encoding a reporter or marker; and (d) genetically engineered host cells that contain any of the foregoing expression vectors and thereby express the nucleic acid molecules of the invention in the host cell.
Recombinant nucleic acid molecule can contain a sequence encoding a soluble Tango- 67 polypeptide, mature Tango- 67, Tango- 67 having a signal sequence, or the chemokine-like domain of Tango-67. The full length Tango-67 polypeptide, a domain of Tango-67, or a fragment thereof may be fused to additional polypeptides, as described below. Similarly, the nucleic acid molecules of the invention can encode the mature form of Tango-67 or a form that encodes a polypeptide which facilitates secretion. In the latter instance, the polypeptide is typically referred to as a proprotein, which can be converted into an active form by removal of the signal sequence, for example, within the host cell. Proproteins can be converted into the active form of the protein by removal of the inactivating sequence.
The regulatory elements referred to above include, but are not limited to, inducible and non-inducible promoters, enhancers, operators and other elements, which are known to those skilled in the art, and which drive or otherwise regulate gene expression. Such regulatory elements include but are not limited to the cytomegalovirus hCMV immediate early gene, the early or late promoters of SV40 adenovirus, the lac system, the trp system, the TAC system, the TRC system, the major operator and promoter regions of phage A, the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase, the promoters of acid phosphatase, and the promoters of the yeast α-mating factors . Similarly, the nucleic acid can form part of a hybrid gene encoding additional polypeptide sequences, for example, sequences that function as a marker or reporter. Examples of marker or reporter genes include jβ-lactamase, chloramphenicol acetyltransferase (CAT) , adenosine deaminase (ADA) , aminoglycoside
phosphotransferase (neor, G418r) , dihydrofolate reductase (DHFR) , hygromycin-B-phosphotransferase (HPH) , thymidine kinase (TK) , lacZ (encoding 3-galactosidase) , and xanthine guanine phosphoribosyltransferase (XGPRT) . As with many of the standard procedures associated with the practice of the invention, skilled artisans will be aware of additional useful reagents, for example, of additional sequences that can serve the function of a marker or reporter. Generally, the hybrid polypeptide will include a first portion and a second portion; the first portion being a Tango- 67 polypeptide and the second portion being, for example, the reporter described above or an immunoglobulin constant region.
The expression systems that may be used for purposes of the invention include, but are not limited to, microorganisms such as bacteria (for example, E. coli and B . subtilis) transformed with recombinant bacteriophage DNA, plasmid DNA, or cosmid DNA expression vectors containing the nucleic acid molecules of the invention; yeast (for example, Saccharoniyces and Pichia) transformed with recombinant yeast expression vectors containing the nucleic acid molecules of the invention (preferably containing the nucleic acid sequence encoding Tango-67 (contained within SEQ ID NO:l)); insect cell systems infected with recombinant virus expression vectors (for example, baculovirus) containing the nucleic acid molecules of the invention; plant cell systems infected with recombinant virus expression vectors (for example, cauliflower mosaic virus (CaMV) and tobacco mosaic virus (TMV) ) or transformed with recombinant plasmid expression vectors (for example, Ti plasmid) containing Tango- 67 nucleotide sequences; or mammalian cell systems (for example, COS, CHO, BHK, 293, VERO, HeLa, MDCK, WI38, and NIH 3T3 cells) harboring recombinant expression constructs containing promoters
derived from the genome of mammalian cells (for example, the metallothionein promoter) or from mammalian viruses (for example, the adenovirus late promoter and the vaccinia virus 7.5K promoter) . In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the gene product being expressed. For example, when a large quantity of such a protein is to be produced, for the generation of pharmaceutical compositions containing Tango-67 polypeptides or for raising antibodies to those polypeptides, vectors that are capable of directing the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited to, the E. coli expression vector pUR278 (Ruther et al . , EMBO J. 2:1791, 1983), in which the coding sequence of the insert may be ligated individually into the vector in frame with the lacZ coding region so that a fusion protein is produced; pIN vectors (Inouye and Inouye, Nucleic Acids Res . 13:3101-3109, 1985; Van Heeke and Schuster, J. Biol . Chem . 264:5503-5509, 1989); and the like. pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST) . In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.
In an insect system, Autographa calif omica nuclear polyhidrosis virus (AcNPV) can be used as a vector to express foreign genes. The virus grows in Spodoptera frugiperda cells. The coding sequence of the insert may be cloned individually into non-essential
regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter) . Successful insertion of the coding sequence will result in inactivation of the polyhedrin gene and production of non-occluded recombinant virus (i.e., virus lacking the proteinaceous coat coded for by the polyhedrin gene) . These recombinant viruses are then used to infect Spodoptera frugiperda cells in which the inserted gene is expressed. (for example, see Smith et al . , J. Virol . 46:584, 1983; Smith, U.S. Patent No. 4,215,051).
In mammalian host cells, a number of viral -based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the nucleic acid molecule of the invention may be ligated to an adenovirus transcription/translation control complex, for example, the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by in vi tro or in vivo recombination. Insertion in a non-essential region of the viral genome (for example, region El or E3) will result in a recombinant virus that is viable and capable of expressing a Tango- 67 gene product in infected hosts (for example, see Logan and Shenk, Proc . Na tl . Acad . Sci . USA 81:3655-3659, 1984). Specific initiation signals may also be required for efficient translation of inserted nucleic acid molecules . These signals include the ATG initiation codon and adjacent sequences. In cases where an entire gene or cDNA, including its own initiation codon and adjacent sequences, is inserted into the appropriate expression vector, no additional translational control signals may be needed. However, in cases where only a portion of the coding sequence is inserted, exogenous translational control signals, including, perhaps, the ATG initiation codon, must be
provided. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (see Bittner et al . , Methods in Enzymol . 153:516-544, 1987). In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (for example, glycosylation) and processing (for example, cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post- translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used. The mammalian cell types listed above are among those that could serve as suitable host cells.
For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express the Tango-67 sequences described above may be engineered. Rather than using expression vectors which contain viral origins of replication, host ceils can be transformed with DNA controlled by appropriate expression control elements (for example, promoter, enhancer sequences, transcription
terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method can advantageously be used to engineer cell lines which express Tango-67. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that affect the endogenous activity of the gene product . A number of selection systems can be used. For example, the herpes simplex virus thymidine kinase (Wigler, et al . , Cell 11:223, 1977), hypoxanthine-guanine phosphoribosyltransferase (Szybalska and Szybalski, Proc . Natl . Acad . Sci . USA 48:2026, 1962), and adenine phosphoribosyltransferase (Lowy, et al . , Cell 22:817,
1980) genes can be employed in tk" , hgprt" or aprt" cells, respectively. Also, anti-metabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler et al., Proc . Natl . Acad . Sci . USA 77:3567, 1980; O'Hare et al., Proc . Natl . Acad . Sci . USA 78:1527, 1981); gpt, which confers resistance to mycophenolic acid (Mulligan and Berg, Proc . Na tl . Acad . Sci . USA 78:2072, 1981); neo, which confers resistance to the aminoglycoside G-418 (Colberre-Garapin et al . , J. Mol . Biol . 150:1, 1981); and hygro, which confers resistance to hygromycin (Santerre et al., Gene 30:147, 1984).
Alternatively, any fusion protein may be readily purified by utilizing an antibody specific for the fusion protein being expressed. For example, a system described
by Janknecht et al . allows for the ready purification of non-denatured fusion proteins expressed in human cell lines { Proc . Natl . Acad . Sci . USA 88: 8972-8976, 1991). In this system, the gene of interest is subcloned into a vaccinia recombination plasmid such that the gene's open reading frame is translationally fused to an amino- terminal tag consisting of six histidine residues. Extracts from cells infected with recombinant vaccinia virus are loaded onto Ni2+ ■ nitriloacetic acid-agarose columns and histidine-tagged proteins are selectively eluted with imidazole-containing buffers.
Tango-67 nucleic acid molecules are useful for diagnosis of disorders associated with aberrant expression of Tango-67. Tango-67 nucleic acid molecules are useful in genetic mapping.
Tango-67 Polypeptides
The Tango- 67 polypeptides described herein are those encoded by any of the nucleic acid molecules described above and include Tango-67 fragments, mutants, truncated forms, and fusion proteins. These polypeptides can be prepared for a variety of uses, including but not limited to the generation of antibodies, as reagents in diagnostic assays, for the identification of other cellular gene products or compounds that can modulate the activity or expression of Tango- 67, and as pharmaceutical reagents useful for the treatment of disorders associated with aberrant expression or activity of Tango-67.
Preferred polypeptides are substantially pure Tango- 67 polypeptides, including those that correspond to the polypeptide with an intact signal sequence, the secreted form of the polypeptide of the human Tango- 67 polypeptide. Especially preferred are polypeptides that are soluble under normal physiological conditions.
The invention also encompasses polypeptides that are functionally equivalent to Tango-67. These polypeptides are equivalent to Tango- 67 m that they are capable of carrying out one or more of the functions of Tango-67 m a biological system. Preferred Tango-67 polypeptides have 20%, 40%, 50%, 75%, 80%, or even 90% of the activity of the full-length, mature human form of Tango- 67. Such comparisons are generally based on an assay of biological activity m which equal concentrations of the polypeptides are used and compared. The comparison can also be based on the amount of the polypeptide required to reach 50% of the maximal stimulation obtainable.
Functionally equivalent proteins can be those, for example, that contain additional or substituted ammo acid residues. Substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved. Ammo acids that are typically considered to provide a conservative substitution for one another are specified m the summary of the invention.
Polypeptides that are functionally equivalent to Tango- 67 (SEQ ID NO: 2) can be made using random mutagenesis techniques well known to those skilled the art (and the resulting mutant Tango- 67 proteins can be tested for activity) . It is more likely, however, that such polypeptides will be generated by site-directed mutagenesis (again using techniques well known to those skilled m the art) . These polypeptides may have an increased function, i . e . , a greater ability to inhibit cellular proliferation, or to evoke an inflammatory response. Such polypeptides can be used to protect progenitor cells from the effects of chemotherapy and/or radiation therapy.
To design functionally equivalent polypeptides, it is useful to distinguish between conserved positions and variable positions. This can be done by aligning the sequence of Tango-67 cDNAs that were obtained from various organisms. Skilled artisans will recognize that conserved amino acid residues are more likely to be necessary for preservation of function. Thus, it is preferable that conserved residues are not altered.
Mutations within the Tango- 67 coding sequence can be made to generate Tango- 67s that are better suited for expression in a selected host cell. For example, N- linked glycosylation sites can be altered or eliminated to achieve, for example, expression of a homogeneous product that is more easily recovered and purified from yeast hosts which are known to hyperglycosylate N-linked sites. To this end, a variety of amino acid substitutions at one or both of the first or third amino acid positions of any one or more of the glycosylation recognition sequences which occur (in N-X-S or N-X--) , and/or an amino acid deletion at the second position of any one or more of such recognition sequences, will prevent glycosylation at the modified tripeptide sequence (see, for example, Miyaj i a et al . , EMBO J. 5:1193, 1986) . The polypeptides of the invention can be expressed fused to another polypeptide, for example, a marker polypeptide or fusion partner. For example, the polypeptide can be fused to a hexa-histidine tag to facilitate purification of bacterially expressed protein or a hemagglutinin tag to facilitate purification of protein expressed in eukaryotic cells.
The polypeptides of the invention can be chemically synthesized (for example, see Creighton, "Proteins: Structures and Molecular Principles," W.H. Freeman & Co., NY, 1983), or, perhaps more
advantageously, produced by recombinant DNA technology as described herein. For additional guidance, skilled artisans may consult Ausubel et al . ( supra) , Sambrook et al . ("Molecular Cloning, A Laboratory Manual," Cold Spring Harbor Press, Cold Spring Harbor, NY, 1989), and, particularly for examples of chemical synthesis Gait, M.J. Ed. ("Oligonucleotide Synthesis," IRL Press, Oxford, 1984) .
The invention also features polypeptides that interact with Tango-67 (and the genes that encode them) and thereby alter the function of Tango-67. Interacting polypeptides can be identified using methods known to those skilled in the art. One suitable method is the "two-hybrid system," which detects protein interactions in vivo (Chien et al . , Proc . Na tl . Acad . Sci . USA, 88:9578, 1991) . A kit for practicing this method is available from Clontech (Palo Alto, CA) .
Tango- 67 polypeptides are useful for growth promotion. Accordingly they have applications in wound healing, tissue repair, implant fixation, and stimulation of bone growth.
Transgenic animals
Tango- 67 polypeptides can also be expressed in transgenic animals. These animals represent a model system for the study of disorders that are caused by or exacerbated by overexpression or underexpression of Tango- 67, and for the development of therapeutic agents that modulate the expression or activity of Tango-67. Transgenic animals can be farm animals (pigs, goats, sheep, cows, horses, rabbits, and the like) rodents (such as rats, guinea pigs, and mice), non-human primates (for example, baboons, monkeys, and chimpanzees), and domestic animals (for example, dogs and cats) . Transgenic mice are especially preferred.
Any technique known m the art can be used to introduce a Tango- 67 transgene into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear micromiection (U.S. Pat. No. 4,873,191); retrovirus mediated gene transfer into germ lines (Van der Putten et al . , Proc . Natl . Acad . Sci . , USA 82:6148, 1985); gene targeting into embryonic stem cells (Thompson et al . , Cell 56:313, 1989); and electroporation of embryos (Lo, Mol . Cell . Biol . 3:1803, 1983).
The present invention provides for transgenic animals that carry the Tango- 67 transgene m all their cells, as well as animals that carry the transgene in some, but not all of their cells. That is, the invention provides for mosaic animals. The transgene can be integrated as a single transgene or in concatamers, e.g., head-to-head tandems or head-to-tail tandems. The transgene can also be selectively introduced into and activated a particular cell type (Lasko et al . , Proc . Natl . Acad . Sci . USA 89:6232, 1992). The regulatory sequences required for such a cell -type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art . When it is desired that the Tango- 67 transgene be integrated into the chromosomal site of the endogenous Tango-67 gene, gene targeting is preferred. Briefly, when such a technique is to be used, vectors containing some nucleotide sequences homologous to an endogenous Tango- 67 gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous gene. The transgene also can be selectively introduced into a particular cell type, thus inactivating the endogenous
Tango-67 gene in only that cell type (Gu et al . , Science 265:103, 1984) . The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. These techniques are useful for preparing "knock outs" having no functional Tango- 67 gene.
Once transgenic animals have been generated, the expression of the recombinant Tango- 67 gene can be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to determine whether integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, in si tu hybridization analysis, and RT-PCR. Samples of Tango- 67 gene- expressing tissue can also be evaluated immunocytochemically using antibodies specific for the Tango-67 transgene product.
For a review of techniques that can be used to generate and assess transgenic animals, skilled artisans can consult Gordon ( Intl . Rev. Cytol . 115:171-229, 1989), and may obtain additional guidance from, for example:
Hogan et al . "Manipulating the Mouse Embryo" (Cold Spring Harbor Press, Cold Spring Harbor, NY, 1986; Krimpenfort et al . , Bio/Technology 9:86, 1991; Palmiter et al . , Cell 41:343, 1985; Kraemer et al . , "Genetic Manipulation of the Early Mammalian Embryo," Cold Spring Harbor Press, Cold Spring Harbor, NY, 1985; Hammer et al . , Nature 315:680, 1985; Purcel et al . , Sci ence, 244:1281, 1986; Wagner et al . , U.S. Patent No. 5,175,385; and Krimpenfort et al . , U.S. Patent No. 5,175,384 (the latter two publications are hereby incorporated by reference) .
Antι-Tango-67 Antibodies
Human Tango- 67 polypeptides (or lmmunogenic fragments or analogs) can be used to raise antibodies useful m the invention; such polypeptides can be produced by recombinant techniques or synthesized (see, for example, "Solid Phase Peptide Synthesis," supra ; Ausubel et al . , supra) In general, the peptides can be coupled to a carrier protein, such as KLH, as described m Ausubel et al . , supra , mixed with an adjuvant, and injected into a host mammal. Antibodies can be purified by peptide antigen affinity chromatography.
In particular, various host animals can be immunized by injection with a Tango-67 protein or polypeptide. Host animals include rabbits, mice, guinea pigs, and rats. Various adjuvants that can be used to increase the immunological response depend on the host species and include Freund's adjuvant (complete and incomplete) , mineral gels such as aluminum hydroxide, surface active substances such as lysolecithm, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanm, and dmitrophenol . Potentially useful human adjuvants include BCG (bacille Calmette-Guerm) and CoryneJbac eriU-n parvum Polyclonal antibodies are heterogeneous populations of antibody molecules that are contained m the sera of the immunized animals.
Antibodies withm the invention therefore include polyclonal antibodies and, m addition, monoclonal antibodies, humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab')2 fragments, and molecules produced using a Fab expression library.
Monoclonal antibodies, which are homogeneous populations of antibodies to a particular antigen, can be prepared using the Tango- 67 proteins described above and standard hybπdoma technology (see, for example, Kohler et al., Na ture 256:495, 1975; Kohler et al . , Eur. J.
Immunol . 6:511, 1976; Kohler et al . , Eur. J. Immunol . 6:292, 1976; Hammerling et al . , "Monoclonal Antibodies and T Cell Hybridomas," Elsevier, NY, 1981; Ausubel et al . , supra) . In particular, monoclonal antibodies can be obtained by any technique that provides for the production of antibody molecules by continuous cell lines in culture such as described in Kohler et al . , Nature 256:495, 1975, and U.S. Patent No. 4,376,110; the human B-cell hybridoma technique (Kosbor et al . , Immunology
Today 4:72, 1983; Cole et al . , Proc . Na tl . Acad . Sci . USA 80:2026, 1983), and the EBV-hybridoma technique (Cole et al . , "Monoclonal Antibodies and Cancer Therapy," Alan R. Liss, Inc., pp. 77-96, 1983) . Such antibodies can be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD and any subclass thereof . The hybridoma producing the mAb of this invention may be cultivated in vi tro or in vivo . The ability to produce high titers of mAbs in vivo makes this the presently preferred method of production.
Once produced, polyclonal or monoclonal antibodies are tested for specific Tango-67 recognition by Western blot or immunoprecipitation analysis by standard methods, e.g., as described in Ausubel et al . , supra . Antibodies that specifically recognize and bind to Tango-67 are useful in the invention. For example, such antibodies can be used in an immunoassay to monitor the level of Tango- 67 produced by a mammal (for example, to determine the amount or subcellular location of Tango- 67) . Preferably, antibodies of the invention are produced using fragments of the Tango-67 protein which lie outside highly conserved regions and appear likely to be antigenic, by criteria such as high frequency of charged residues. In one specific example, such fragments are generated by standard techniques of PCR,
and are then cloned into the pGEX expression vector (Ausubel et al . , supra) . Fusion proteins are expressed in E. coli and purified using a glutathione agarose affinity matrix as described in Ausubel, et al . , supra . In some cases it may be desirable to minimize the potential problems of low affinity or specificity of antisera. In such circumstances, two or three fusions can be generated for each protein, and each fusion can be injected into at least two rabbits. Antisera can be raised by injections in a series, preferably including at least three booster injections.
Antisera is also checked for its ability to immunoprecipitate recombinant Tango-67 proteins or control proteins, such as glucocorticoid receptor, CAT, or luciferase.
The antibodies can be used, for example, in the detection of the Tango- 67 in a biological sample as part of a diagnostic assay. Antibodies also can be used in a screening assay to measure the effect of a candidate compound on expression or localization of Tango-67.
Additionally, such antibodies can be used in conjunction with the gene therapy techniques described to, for example, evaluate the normal and/or engineered Tango-67- expressing cells prior to their introduction into the patient. Such antibodies additionally can be used in a method for inhibiting abnormal Tango-67 activity. In addition, techniques developed for the production of "chimeric antibodies" (Morrison et al . , Proc . Natl . Acad . Sci . USA , 81:6851, 1984; Neuberger et al . , Nature, 312:604, 1984; Takeda et al . , Nature, 314:452, 1984) by splicing the genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. A chimeric antibody is a molecule in which different portions are
derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region.
Alternatively, techniques described for the production of single chain antibodies (U.S. Patent Nos . 4,946,778, 4,946,778, and 4,704,692) can be adapted to produce single chain antibodies against a Tango- 67 protein or polypeptide. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide.
Antibody fragments that recognize and bind to specific epitopes can be generated by known techniques. For example, such fragments include but are not limited to F(ab')2 fragments that can be produced by pepsin digestion of the antibody molecule, and Fab fragments that can be generated by reducing the disulfide bridges of F(ab')2 fragments. Alternatively, Fab expression libraries can be constructed (Huse et al . , Science, 246:1275, 1989) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity.
Antibodies to Tango- 67 can, in turn, be used to generate anti-idiotype antibodies that resemble a portion of Tango-67 using techniques well known to those skilled in the art (see, e.g., Greenspan et al . , FASEB J. 7:437, 1993; Nissinoff, J. Immunol . 147:2429, 1991). For example, antibodies that bind to Tango- 67 and competitively inhibit the binding of a ligand of Tango- 67 can be used to generate anti-idiotypes that resemble a ligand binding domain of Tango-67 and, therefore, bind and neutralize a ligand of Tango-67. Such neutralizing anti-idiotypic antibodies or Fab fragments of such anti- idiotypic antibodies can be used in therapeutic regimens. Antibodies can be humanized by methods known in the art. For example, monoclonal antibodies with a
desired binding specificity can be commercially humanized (Scotgene, Scotland; Oxford Molecular, Palo Alto, CA) . Fully human antibodies, such as those expressed in transgenic animals are also features of the invention (Green et al . , Nature Genetics 7:13-21, 1994; see also U.S. Patents 5,545,806 and 5,569,825, both of which are hereby incorporated by reference) .
The methods described herein in which anti-Tango- 67 antibodies are employed may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one specific Tango-67 nucleotide sequence or antibody reagent described herein, which may be conveniently used, for example, in clinical settings, to diagnose patients exhibiting symptoms of the disorders described below.
Antisense Nucleic Acids
Treatment regimes based on an "antisense" approach involve the design of oligonucleotides (either DNA or RNA) that are complementary to Tango- 67 mRNA. These oligonucleotides bind to the complementary Tango-67 mRNA transcripts and prevent translation. Absolute complementarity, although preferred, is not required. A sequence "complementary" to a portion of an RNA, as referred to herein, means a sequence having sufficient complementarily to be able to hybridize with the RNA, forming a stable duplex; in the case of double-stranded antisense nucleic acids, a single strand of the duplex DNA may be tested, or triplex formation may be assayed. The ability to hybridize will depend on both the degree of complementarily and the length of the antisense nucleic acid. Generally, the longer the hybridizing nucleic acid, the more base mismatches with an RNA it may contain and still form a stable duplex (or triplex, as the case may be) . One skilled in the art can ascertain a
tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.
Oligonucleotides that are complementary to the 5' end of the message, e.g., the 5' untranslated sequence up to and including the AUG initiation codon, should work most efficiently at inhibiting translation. However, sequences complementary to the 3' untranslated sequences of mRNAs recently have been shown to be effective at inhibiting translation of mRNAs as well (Wagner, Na ture 372:333, 1984) . Thus, oligonucleotides complementary to either the 5' or 3' non-translated, non-coding regions of the Tango-67 gene, e.g., the human gene shown in the Figure could be used in an antisense approach to inhibit translation of endogenous Tango- 67 mRNA.
Oligonucleotides complementary to the 5' untranslated region of the mRNA should include the complement of the AUG start codon.
Antisense oligonucleotides complementary to mRNA coding regions are less efficient inhibitors of translation but could be used in accordance with the invention. Whether designed to hybridize to the 5', 3', or coding region of Tango-67 mRNA, antisense nucleic acids should be at least six nucleotides in length, and are preferably oligonucleotides ranging from 6 to about 50 nucleotides in length. In specific aspects the oligonucleotide is at least 10 nucleotides, at least 17 nucleotides, at least 25 nucleotides, or at least 50 nucleotides. Regardless of the choice of target sequence, it is preferred that in vi tro studies are first performed to quantitate the ability of the antisense oligonucleotide to inhibit gene expression. It is preferred that these studies utilize controls that distinguish between antisense gene inhibition and nonspecific biological
effects of oligonucleotides. It is also preferred that these studies compare levels of the target RNA or protein with that of an internal control RNA or protein. Additionally, it is envisioned that results obtained using the antisense oligonucleotide are compared with those obtained using a control oligonucleotide. It is preferred that the control oligonucleotide is of approximately the same length as the test oligonucleotide and that the nucleotide sequence of the oligonucleotide differs from the antisense sequence no more than is necessary to prevent specific hybridization to the target sequence .
The oligonucleotides can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule, hybridization, etc. The oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo) , or agents facilitating transport across the cell membrane (as described, e.g., in Letsinger et al . , Proc . Natl . Acad . Sci . USA 86:6553, 1989; Lemaitre et al . , Proc. Natl . Acad . Sci . USA 84:648, 1987; PCT Publication No. WO 88/09810) or the blood-brain barrier (see, for example, PCT Publication No. WO 89/10134) , or hybridization-triggered cleavage agents (see, for example, Krol et al . , BioTechniques 6:958, 1988), or intercalating agents (see, for example, Zen, Pharm . Res . 5:539, 1988) . To this end, the oligonucleotide can be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking ageπ_ , transport agent, or hybridization-triggered cleavage agent.
The antisense oligonucleotide may comprise at least one modified base moiety which is selected from the
group including, but not limited to, 5-fluorouracil , 5-bromouracil , 5-chlorouracil , 5-iodouracil , hypoxanthine, xantine, 4-acetylcytosine, 5- (carboxyhydroxylmethyl) uracil, 5- carboxymethylaminomethyl-2-thiouridine, 5-carboxymethyl- aminomethyluracil , dihydrouracil , beta-D- galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2 , 2-dimethylguanine, 2-methyladenine, 2 -methylguanine, 3 -methylcytosine, 5 -methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil , 5-methoxyaminomethyl- 2-thiouracil , beta-D-mannosylqueosine, 5' -methoxycarboxymethyluracil , 5-methoxyuracil , 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v) , wybutoxosine , pseudouracil , queosine,
2-thiocytosine, 5-methyl-2-theouracil , 2 -thiouracil , 4- thiouracil, 5-methyluracil , uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v) , 5-methyl- 2-thiouracil , 2- (3-amino-3-N-2 -carboxypropl) uracil, (acp3)w, and 2 , 6-diaminopurine .
The antisense oligonucleotide may also comprise at least one modified sugar moiety selected from the group including, but not limited to, arabinose, 2-fluoroarabinose, xylulose, and hexose . In yet another embodiment, the antisense oligonucleotide comprises at least one modified phosphate backbone selected from the group consisting of a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal, or an analog of any of these backbones.
In yet another embodiment, the antisense oligonucleotide is an α-anomeric oligonucleotide. An o.-anomeric oligonucleotide forms specific double-stranded
hybrids with complementary RNA in which, contrary to the usual jβ-units, the strands run parallel to each other (Gautier et al . , Nucl . Acids . Res . 15:6625, 1987). The oligonucleotide is a 2 ' -O-methylribonucleotide (Inoue et al . , Nucl . Acids Res . 15:6131, 1987), or a chimeric RNA-DNA analog (Inoue et al . , FEBS Lett . 215:327, 1987).
Antisense oligonucleotides of the invention can be synthesized by standard methods known in the art, e.g., by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides can be synthesized by the method of Stein et al . (Nucl . Acids Res . 16:3209, 1988), and methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin et al . , Proc . Natl . Acad . Sci . USA 85:7448, 1988) .
While antisense nucleotides complementary to the Tango-67 coding region sequence could be used, those complementary to the transcribed untranslated region are most preferred.
The antisense molecules should be delivered to cells that express Tango-67 in vivo, e.g., cells of the heart, skeletal muscle, thymus, spleen, and small intestine. A number of methods have been developed for delivering antisense DNA or RNA to cells; e.g., antisense molecules can be injected directly into the tissue site, or modified antisense molecules, designed to target the desired cells (e.g., antisense linked to peptides or antibodies that specifically bind receptors or antigens expressed on the target cell surface) can be administered systemically.
However, it is often difficult to achieve intracellular concentrations of the antisense molecule sufficient to suppress translation of endogenous mRNAs. Therefore, a preferred approach uses a recombinant DNA
construct in which the antisense oligonucleotide is placed under the control of a strong pol III or pol II promoter. The use of such a construct to transfect target cells in the patient will result in the transcription of sufficient amounts of single stranded RNAs that will form complementary base pairs with the endogenous Tango- 67 transcripts and thereby prevent translation of the Tango- 67 mRNA. For example, a vector can be introduced in vivo such that it is taken up by a cell and directs the transcription of an antisense RNA. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA.
Such vectors can be constructed by recombinant DNA technology methods standard in the art . Vectors can be plasmid, viral, or others known in the art, used for replication and expression in mammalian cells. Expression of the sequence encoding the antisense RNA can be by any promoter known in the art to act in mammalian, preferably human cells. Such promoters can be inducible or constitutive. Such promoters include, but are not limited to: the SV40 early promoter region (Bernoist et al . , Nature 290:304, 1981); the promoter contained in the 3 ' long terminal repeat of Rous sarcoma virus (Yamamoto et al . , Cell 22:787-797 , 1988); the herpes thyτnidine kinase promoter (Wagner et al . , Proc . Natl . Acad . Sci . USA 78:1441, 1981); or the regulatory sequences of the metallothionein gene (Brinster et al . , Nature 296:39, 1988) . Ribozymes
Ribozyme molecules designed to catalytically cleave Tango- 67 mRNA transcripts also can be used to prevent translation of Tango- 67 mRNA and expression of Tango-67 (see, e.g., PCT Publication WO 90/11364; Saraver et al . , Science 247:1222, 1990). While various ribozymes
that cleave mRNA at site-specific recognition sequences can be used to destroy Tango- 67 mRNAs, the use of hammerhead ribozymes is preferred. Hammerhead ribozymes cleave mRNAs at locations dictated by flanking regions that form complementary base pairs with the target mRNA. The sole requirement is that the target mRNA have the following sequence of two bases: 5'-UG-3'. The construction and production of hammerhead ribozymes is well known in the art (Haseloff et al . , Na ture 334:585, 1988) . There are numerous examples of potential hammerhead ribozyme cleavage sites within the nucleotide sequence of human Tango-67 cDNA. Preferably, the ribozyme is engineered so that the cleavage recognition site is located near the 5' end of the Tango-67 mRNA, i.e., to increase efficiency and minimize the intracellular accumulation of non-functional mRNA transcripts .
The ribozymes of the present invention also include RNA endoribonucleases (hereinafter "Cech-type ribozymes"), such as the one that occurs naturally in Tet-ra y_τ.e-ia Thermophila (known as the IVS or L-19 IVS RNA) , and which has been extensively described by Cech and his collaborators (Zaug et al . , Sci ence 224:574, 1984; Zaug et al . , Sci ence, 231:470, 1986; Zug et al . , Nature 324:429, 1986; PCT Application No. WO 88/04300; and Been et al . , Cell 47:207, 1986). The Cech-type ribozymes have an eight base-pair sequence that hybridizes to a target RNA sequence, whereafter cleavage of the target RNA takes place. The invention encompasses those Cech-type ribozymes that target eight base-pair active site sequences present in Tango-67.
As in the antisense approach, the ribozymes can be composed of modified oligonucleotides (e.g., for improved stability, targeting, etc.), and should be delivered to cells which express the Tango-67 in vi vo, e.g., heart,
skeletal muscle, thymus, spleen, and small intestine. A preferred method of delivery involves using a DNA construct "encoding" the ribozyme under the control of a strong constitutive pol III or pol II promoter, so that transfected cells will produce sufficient quantities of the ribozyme to destroy endogenous Tango-67 messages and inhibit translation. Because ribozymes, unlike antisense molecules, are catalytic, a lower intracellular concentration is required for efficiency.
Other Methods for Reducing Tango- 67 Expression Endogenous Tango- 67 gene expression can also be reduced by inactivating or "knocking out" the Tango-67 gene or its promoter using targeted homologous recombination (see, e.g., U.S. Patent No. 5,464,764). For example, a mutant, non-functional Tango-67 (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous Tango- 67 gene (either the coding regions or regulatory regions of the Tango- 67 gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express Tango-67 in vivo . Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the Tango- 67 gene. Such approaches are particularly suited for use in the agricultural field where modifications to ES (embryonic stem) cells can be used to generate animal offspring with an inactive Tango- 67. However, this approach can be adapted for use in humans, provided the recombinant DNA constructs are directly administered or targeted to the required site in vivo using appropriate viral vectors.
Alternatively, endogenous Tango- 67 gene expression can be reduced by targeting deoxyribonucleotide sequences complementary to the regulatory region of the Tango-67 gene (i.e., the Tango-67 promoter and/or enhancers) to
form triple helical structures that prevent transcription of the Tango- 67 gene in target cells in the body (Helene Anticancer Drug Res . 6:569, 1981; Helene et al . , Ann . N. Y. Acad . Sci . 660:27, 1992; and Maher, Bioassays 14:807, 1992) .
Of course, in some circumstances, including certain phases of many of the above-described conditions, it may be desirable to enhance Tango-67 function, e.g., to recruit immune cells that will resolve the primary infection or mediate an anti-tumor response.
Detecting Proteins Associated with Tango-67 The invention also features polypeptides which interact with Tango- 67. Any method suitable for detecting protein-protein interactions may be employed for identifying transmembrane proteins, intracellular, or extracellular proteins that interact with Tango-67. Among the traditional methods which may be employed are co-immunoprecipitation, crosslinking and co-purification through gradients or chromatographic columns of cell lysates or proteins obtained from cell lysates and the use of Tango-67 to identify proteins in the lysate that interact with Tango-67. For these assays, the Tango-67 polypetide can be a full length Tango-67, a soluble extracellular domain of Tango- 67, or some other suitable Tango- 67 polypeptide. Once isolated, such an interacting protein can be identified and cloned and then used, in conjunction with standard techniques, to identify proteins with which it interacts. For example, at least a portion of the amino acid sequence of a protein which interacts with the Tango-67 can be ascertained using techniques well known to those of skill in the art, such as via the Edman degradation technique. The amino acid sequence obtained may be used as a guide for the generation of oligonucleotide mixtures that can be used
to screen for gene sequences encoding the interacting protein. Screening may be accomplished, for example, by standard hybridization or PCR techniques. Techniques for the generation of oligonucleotide mixtures and the screening are well-known. (Ausubel, supra ; and "PCR
Protocols: A Guide to Methods and Applications," Innis et al . , eds . Academic Press, Inc., NY, 1990).
Additionally, methods may be employed which result directly in the identification of genes which encode proteins which interact with Tango-67. These methods include, for example, screening expression libraries, in a manner similar to the well known technique of antibody probing of λgtll libraries, using labeled Tango-67 polypeptide or a Tango-67 fusion protein, e.g., a Tango- 67 polypeptide or domain fused to a marker such as an enzyme, fluorescent dye, a luminescent protein, or to an IgFc domain.
There are also methods which are capable of detecting protein interaction. A method which detects protein interactions in vivo is the two-hybrid system (Chien et al . , Proc . Na tl . Acad . Sci . USA , 88:9578, 1991) . A kit for practicing this method is available from Clontech (Palo Alto, CA) .
Briefly, utilizing such a system, plasmids are constructed that encode two hybrid proteins : one plasmid includes a nucleotide sequence encoding the DNA-binding domain of a transcription activator protein fused to a nucleotide sequence encoding Tango- 67, a Tango- 67 polypeptide, or a Tango- 67 fusion protein, and the other plasmid includes a nucleotide sequence encoding the transcription activator protein's activation domain fused to a cDNA encoding an unknown protein which has been recombined into this plasmid as part of a cDNA library. The DNA-binding domain fusion plasmid and the cDNA library are transformed into a strain of the yeast
Saccharomyces cerevisiae that contains a reporter gene (e.g., HBS or LacZ) whose regulatory region contains the transcription activator's binding site. Either hybrid protein alone cannot activate transcription of the reporter gene : the DNA-binding domain hybrid cannot because it does not provide activation function and the activation domain hybrid cannot because it cannot localize to the activator's binding sites. Interaction of the two hybrid proteins reconstitutes the functional activator protein and results in expression of the reporter gene, which is detected by an assay for the reporter gene product .
The two-hybrid system or related methodology may be used to screen activation domain libraries for proteins that interact with the "bait" gene product. By way of example, and not by way of limitation, Tango-67 may be used as the bait gene product . Total genomic or cDNA sequences are fused to the DNA encoding an activation domain. This library and a plasmid encoding a hybrid of bait Tango- 67 gene product fused to the DNA- binding domain are cotransformed into a yeast reporter strain, and the resulting transformants are screened for those that express the reporter gene. For example, a bait Tango- 67 gene sequence, such as Tango-67 or a domain of Tango- 67 can be cloned into a vector such that it is translationally fused to the DNA encoding the DNA-binding domain of the GAL4 protein. These colonies are purified and the library plasmids responsible for reporter gene expression are isolated. DNA sequencing is then used to identify the proteins encoded by the library plasmids. A cDNA library of the cell line from which proteins that interact with bait Tango- 67 gene product are to be detected can be made using methods routinely practiced in the art. According to the particular system described herein, for example, the cDNA fragments can be
inserted into a vector such that they are translationally fused to the transcriptional activation domain of GAL4. This library can be co-transformed along with the bait Tango-67 gene-GAL4 fusion plasmid into a yeast strain which contains a lacZ gene driven by a promoter which contains GAL4 activation sequence. A cDNA encoded protein, fused to GAL4 transcriptional activation domain, that interacts with bait Tango- 67 gene product will reconstitute an active GAL4 protein and thereby drive expression of the HIS3 gene. Colonies which express HIS3 can then be purified from these strains, and used to produce and isolate the bait Tango-67 gene-interacting protein using techniques routinely practiced in the art.
Identification of a Tango-67 Receptor A Tango-67 receptor can be identified as follows. First cells or tissues which bind Tango-67 are identified. An expression library is prepared using mRNA isolated from Tango-67 binding cells. The expression library is used to transfect; eulcaryatic cells, e.g., CHO cells. Detectably labelled Tango-67 and, clones which bind Tango- 67 are isolated and purified. The expression plasmid is then isolated from the Tango-67- binding clones. These expression plasmids will encode putaslive Tango-67 receptors. Cells or tissues bearing a Tango-67 receptor can be identified by exposing detectably labelled Tango-67 to various cells lines and tissues. Alternatively a microphysiometer can be used to determine whether a selected cells responds to the presence of a cell receptor ligand (McConnel et al . , Sci ence 257:1906, 1992) .
Compounds which bind Tango-67 can be identified using any standard binding assay. For example, candidate compounds can be bound to a solid support. Tango-67 is then exposed to the immobilized compound and binding is measured (European Patent Application 84/03564) .
Effective Dose
Toxicity and therapeutic efficacy of the polypeptides of the invention and the compounds that modulate their expression or activity can be determined by standard pharmaceutical procedures, using either cells in culture or experimental animals to determine the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population) . The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50. Polypeptides or other compounds that exhibit large therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.
The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans . The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the
IC50 (that is, the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.
Formulations and Use
Pharmaceutical compositions for use in accordance with the present invention may be formulated in conventional manner using one or more physiologically acceptable carriers or excipients.
Thus, the compounds and their physiologically acceptable salts and solvates may be formulated for administration by inhalation or insufflation (either through the mouth or the nose) or oral, buccal, parenteral or rectal administration.
For oral administration, the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (for example, pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose) ; fillers (for example, lactose, microcrystalline cellulose or calcium hydrogen phosphate) ; lubricants (for example, magnesium stearate, talc or silica); disintegrants (for example, potato starch or sodium starch glycolate) ; or wetting agents (for example, sodium lauryl sulphate) . The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable
additives such as suspending agents (for example, sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (for example, lecithin or acacia); non-aqueous vehicles (for example, almond oil, oily esters, ethyl alcohol or fractionated vegetable oils) ; and preservatives (for example, methyl or propyl - p-hydroxybenzoates or sorbic acid) . The preparations may also contain buffer salts, flavoring, coloring and sweetening agents as appropriate. Preparations for oral administration may be suitably formulated to give controlled release of the active compound.
For buccal administration the compositions may take the form of tablets or lozenges formulated in conventional manner. For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, for example, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, for example, gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch. The compounds may be formulated for parenteral administration by injection, for example, by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, for example, in ampoules or in multi -dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as
suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, for example, sterile pyrogen-free water, before use. The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, for example, containing conventional suppository bases such as cocoa butter or other glycerides .
In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack may for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. The therapeutic compositions of the invention can also contain a carrier or excipient, many of which are known to skilled artisans. Excipients which can be used include buffers (for example, citrate buffer, phosphate buffer, acetate buffer, and bicarbonate buffer) , amino acids, urea, alcohols, ascorbic acid, phospholipids, proteins (for example, serum albumin), EDTA, sodium chloride, liposomes, mannitol, sorbitol, and glycerol . The nucleic acids, polypeptides, antibodies, or modulatory compounds of the invention can be administered by any standard route of administration. For example,
administration can be parenteral, intravenous, subcutaneous, intramuscular, intracranial , intraorbital , opthalmic, intraventricular, intracapsular, intraspinal, intracisternal , intraperitoneal , transmucosal , or oral. The modulatory compound can be formulated in various ways, according to the corresponding route of administration. For example, liquid solutions can be made for ingestion or injection; gels or powders can be made for ingestion, inhalation, or topical application. Methods for making such formulations are well known and can be found in, for example, "Remington's Pharmaceutical Sciences." It is expected that the preferred route of administration will be intravenous.
Examples Example 1 describes the identification and sequencing of a human Tango-67 gene. Example 2 describes the characterization of Tango-67, particularly the expression pattern.
Example 1: Cloning of the Tango-67 Gene Human astrocytes (obtained from Clonetics
Corporation; San Diego, CA) were expanded in culture with Astrocyte Growth Media (AGN; Clonetics) according to the recommendations of the supplier. When the cells reached ~80-90% confluence, they were stimulated v:ith 200 units/ml Interleukin Iβ (Boehringer Mannheim, Indianapolis, IN) and cycloheximide (CHI; 40 micrograms/ml) for 4 hours. Total RNA was isolated using the RNeasy Midi Kit (Qiagen; Chatsworth, CA) , and the poly A+ fraction was further purified using Oligotex beads (Qiagen) .
Three micrograms of poly A+ RNA were used to synthesize a cDNA library using the Superscript cDNA Synthesis kit (Gibco BRL; Gaithersburg, K ) .
Complementary DNA was directionally clones into the expression plasmid pMET7 using the Sail and NotI sites in the polylinker to construct a plasmid library. Transformants were picked and grown up for single-pass sequencing. Additionally, astrocyte cDNA was ligated into the Sall/NotI sites of the ZipLox vector (Gibco BRL) for construction of a lambda phage cDNA library. A partial cDNA clone that encoded a protein with homology to TSG was identified, and additional screening of the phage library led to the isolation of a full length clone for Tango 67. Tango 67 encodes a protein of 223 amino acids that is 36% identical to D. melanogaster TSG, based on comparisons using the GAP program from GCG (Madison, WI) .
Example 2: Characterization of Tanσo-67
The expression pattern of Tango- 67 was examined as described below.
Analysis of Tanqo-67 expression
The expression of Tango 67 was analyzed using Northern blot hybridization. A 410 base pair (bp) DNA fragment was generated using PCR (corresponding to nucleotides 234 to 643 in SEQ ID NO:l) for use as a probe. The DNA was radioactively labeled with 32P-dCTP using the Prime-It kit (Strategen, LaJolla, CA) according to the instructions of the supplier. Filters containing human mRNA (MTNI and MTNII form Clontech, Palo Alto, CA) were probed in ExpressHyb hybridization solution (Clontech) and washed at high stringency according to using a slight variation of the manufacturer's recommendations. The high stringency wash is 2 x 20 min in 2X SSC, 0.05% SDS at 55°C; then 2 x 20 min in 0. IX SSC, 0.1% SDS at 55°C.
Tango 67 is expressed at variable levels in all tissues examined (spleen, thymus, prostate, testes, ovary, small intestine, colon, PBLs , heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas.) The Tango 67 gene is expressed as two transcripts, an -4.4 kilobase (kb) and -2.4 kb mRNA, in good agreement with the cDNA clones isolated. The relative levels of the two transcripts vary from tissue to tissue, though with the exception of testes, the 4.4 transcript is significantly more abundant . In the testes the levels of the 4.4 and 2.4 kb mRNAs are approximately the same, and an additional hybridizing transcript is seen at -800 bp .
Deposit Information A plasmid containing the human full length nucleotide sequence encoding TANGO 67 was deposited with the American type Culture Collection, Rockville, Maryland, on April 16, 1997 and assigned Accession Number 98410. The subject culture has been deposited under conditions that assure that access to the culture will be available during the pendency of the patent application to one determined by the Commissioner of Patents and Trademarks to be entitled thereto under 37 CFR 1.14 and 35 USC 122. The deposit is available as required by foreign patent laws in countries wherein counterparts of the subject application, or its progeny, are filed. However, it should be understood that the availability of a deposit does not constitute a license to practice the subject invention in derogation of patent rights granted by governmental action.
Further, the subject culture deposit will be stored and made available to the public in accord with the provisions of the Budapest Treaty for the Deposit of
Microorganisms, i.e., it will be stored with all the care necessary to keep it viable and uncontaminated for a period of at least five years after the most recent request for the furnishing of a sample of the deposit, and in any case, for a period of at least 30 (thirty) years after the date of deposit or for the enforceable life of any patent which can issue disclosing the culture plus five years after the last request for a sample from the deposit . The depositor acknowledges the duty to replace the deposit should the depository be unable to furnish a sample when requested, due to the condition of the deposit. All restrictions on the availability to the public of the subject culture deposit will be irrevocably removed upon the granting of a patent disclosing them.
Claims
1. An isolated nucleic acid molecule encoding a Tango- 67 polypeptide.
2. The nucleic acid molecule of claim 1, said molecule encoding mature human Tango-67.
3. The isolated nucleic acid molecule of claim 1, said molecule comprising a nucleotide sequence encoding a polypeptide having sequence that is at least 85% identical to the sequence of SEQ ID NO: 2.
4. The isolated nucleic acid molecule of claim 1, said molecule comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 2.
5. The isolated nucleic acid molecule of claim 1, said molecule comprising the nucleotide sequence of between nucleotide 182 and 850, inclusive, of SEQ ID NO:l.
6. The isolated nucleic acid molecule of claim 1, said molecule hybridizing under stringent conditions to a nucleic acid molecule having the sequence of nucleotides 182 to 850, inclusive, of SEQ ID NO : 1 or its complement .
7. A host cell comprising the isolated nucleic acid molecule of claim 1.
8. A nucleic acid vector comprising the nucleic acid molecule of claim 1.
9. The nucleic acid vector of claim 8, wherein said vector is an expression vector.
10. The vector of claim 9, further comprising a regulatory element .
11. The vector of claim 10, wherein the regulatory element is selected from the group consisting of the cytomegalovirus hCMV immediate early gene, the early promoter of SV25 adenovirus, the late promoter of SV25 adenovirus, the lac system, the trp system, the TAC system, the TRC system, the major operator and promoter regions of phage ╬╗, the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase, the promoters of acid phosphatase, and the promoters of the yeast cv-mating factors.
12. The vector of claim 10, wherein said regulatory element directs tissue-specific expression.
13. The vector of claim 9, further comprising a reporter gene .
14. The vector of claim 13, wherein the reporter gene is selected from the group consisting of 3-lactamase, chloramphenicol acetyltransferase (CAT) , adenosine deaminase (ADA) , aminoglycoside phosphotransferase (neor, G403r) , dihydrofolate reductase (DHFR) , hygromycin-B-phosphotransferase (HPH) , thymidine kinase (TK) , lacZ (encoding 3-galactosidase) , and xanthine guanine phosphoribosyltransferase (XGPRT) .
15. The vector of claim 8, wherein said vector is a plasmid.
16. The vector of claim 8, wherein said vector is a virus .
17. The vector of claim 16, wherein said virus is a retrovirus .
18. A substantially pure Tango- 67 polypeptide.
19. The polypeptide of claim 18, said polypeptide being soluble under physiological conditions.
20. The polypeptide of claim 18, said polypeptide comprising an amino acid sequence that is at least 80% identical to the amino acid sequence of SEQ ID NO: 2.
21. The polypeptide of claim 18, said polypeptide comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 2.
22. The polypeptide of claim 18, said polypeptide comprising an amino acid sequence that is identical to the amino acid sequence of SEQ ID NO: 2.
23. A substantially pure polypeptide comprising a first portion and a second portion, said first portion comprising a Tango-67 polypeptide and said second portion comprising a detectable marker.
24. An antibody that selectively binds to a Tango- 67 polypeptide.
25. The antibody of claim 24, wherein said antibody is a monoclonal antibody.
26. A pharmaceutical composition comprising the polypeptide of claim 18.
27. A method for detecting Tango-67 in a sample, said method comprising:
(a) obtaining a biological sample;
(b) contacting said biological sample with an antibody that specifically binds Tango- 67 under conditions that allow the formation of Tango- 67 -antibody complexes; and
(c) detecting said complexes, if any, as an indication of the presence of Tango-67 in said sample.
28. A method of identifying a compound that modulates the expression of Tango- 67, said method comprising comparing the level of expression of Tango-67 in a cell in the presence and absence of a selected compound, wherein a difference in the level of expression in the presence and absence of said selected compound indicates that said selected compound modulates the expression of Tango-67.
29. A method of identifying a compound that modulates the activity of Tango- 67, said method comprising comparing the level of activity of Tango-67 in a cell in the presence and absence of a selected compound, wherein a difference in the level of activity in the presence and absence of said selected compound indicates that said selected compound modulates the activity of Tango-67.
30. A method for preparing a medicament for treating a patient suffering from a disorder associated with excessive expression or activity of Tango-67, the method comprising admixing a compound which inhibits expression or activity of Tango- 67 with a pharmaceutically acceptable carrier.
31. A method for preparing a medicament for treating a patient suffering from a disorder associated with insufficient expression or activity of Tango-67, the method comprising admixing a compound which increases expression or activity of Tango-67 with a pharmaceutically acceptable carrier.
32. A method for diagnosing a disorder associated with aberrant expression of Tango-67, comprising obtaining a biological sample from a patient and measuring Tango- 67 expression in said biological sample, wherein increased or decreased Tango- 67 expression in said biological sample compared to a control indicates that said patient suffers from a disorder associated with aberrant expression of Tango-67.
33. A method for diagnosing a disorder associated with aberrant activity of Tango- 67, comprising obtaining a biological sample from a patient and measuring Tango-67 activity in said biological sample, wherein increased or decreased Tango-67 activity in said biological sample compared to a control indicates that said patient suffers from a disorder associated with aberrant activity of Tango-67.
34. An isolated nucleic acid molecule which hybridizes to a nucleic acid molecule having the sequence of nucleotides 182 to 850, inclusive, of SEQ ID N0:1 or its complement .
35. An isolated nucleic acid molecule having a sequence which is at least 95% identical to the sequence of nucleotides 182 to 850, inclusive of SEQ ID N0:1.
36. A polypeptide encoded by the nucleic acid molecule of any of claims 34 or 35.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002286934A CA2286934A1 (en) | 1997-04-16 | 1998-04-15 | Novel polypeptides within the growth factor superfamily |
JP54426898A JP2001527397A (en) | 1997-04-16 | 1998-04-15 | Novel polypeptides of the growth factor superfamily |
AU72487/98A AU7248798A (en) | 1997-04-16 | 1998-04-15 | Novel polypeptides within the growth factor superfamily |
EP98919774A EP1005489A4 (en) | 1997-04-16 | 1998-04-15 | Novel polypeptides within the growth factor superfamily |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84365197A | 1997-04-16 | 1997-04-16 | |
US08/843,651 | 1997-04-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998046641A1 WO1998046641A1 (en) | 1998-10-22 |
WO1998046641A9 true WO1998046641A9 (en) | 1999-03-18 |
Family
ID=25290612
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/007603 WO1998046641A1 (en) | 1997-04-16 | 1998-04-15 | Novel polypeptides within the growth factor superfamily |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1005489A4 (en) |
JP (1) | JP2001527397A (en) |
AU (1) | AU7248798A (en) |
CA (1) | CA2286934A1 (en) |
WO (1) | WO1998046641A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0907719A4 (en) * | 1996-03-20 | 2003-02-19 | Human Genome Sciences Inc | Human cytokine polypeptide |
AU6871900A (en) | 1999-09-06 | 2001-04-10 | Chugai Seiyaku Kabushiki Kaisha | Tsg-like gene |
WO2004074483A1 (en) * | 2003-02-20 | 2004-09-02 | Chugai Seiyaku Kabushiki Kaisha | Tsg gene-knockout animal |
AU2017325973A1 (en) * | 2016-09-15 | 2019-03-07 | Acceleron Pharma Inc. | Twisted gastrulation polypeptides and uses thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5408040A (en) * | 1991-08-30 | 1995-04-18 | University Of South Florida | Connective tissue growth factor(CTGF) |
JPH10502534A (en) * | 1994-07-12 | 1998-03-10 | ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド | Connective tissue growth factor-2 |
EP0907719A4 (en) * | 1996-03-20 | 2003-02-19 | Human Genome Sciences Inc | Human cytokine polypeptide |
-
1998
- 1998-04-15 CA CA002286934A patent/CA2286934A1/en not_active Abandoned
- 1998-04-15 JP JP54426898A patent/JP2001527397A/en active Pending
- 1998-04-15 EP EP98919774A patent/EP1005489A4/en not_active Withdrawn
- 1998-04-15 WO PCT/US1998/007603 patent/WO1998046641A1/en not_active Application Discontinuation
- 1998-04-15 AU AU72487/98A patent/AU7248798A/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5989909A (en) | Huchordin and uses thereof | |
US6416974B1 (en) | Tango 71 nucleic acids | |
US20060069246A1 (en) | Tumor necrosis factor receptor related proteins Tango-63d and Tango-63e | |
US6346374B1 (en) | Nucleic acid molecules encoding GLUTX and uses thereof | |
US20080293077A1 (en) | Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic and other uses | |
WO1999006427A1 (en) | Tango-78, tango-79, and tango-81 nucleic acid molecules and polypeptides | |
WO1998007736A9 (en) | Don-1 gene and polypeptides and uses therefor | |
AU4154097A (en) | Don-1 gene and polypeptides and uses therefor | |
US20020112251A1 (en) | Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic and other uses | |
US7057021B2 (en) | Genes encoding caspase recruitment domain polypeptides | |
WO1998046641A9 (en) | Novel polypeptides within the growth factor superfamily | |
WO1998046641A1 (en) | Novel polypeptides within the growth factor superfamily | |
US20020034786A1 (en) | Tango-72 and Tango-77 nucleic acid molecules and polypeptides | |
EP1226170B1 (en) | Human chordin and polynucleotides encoding the same | |
US20040265970A1 (en) | Don-1 gene and polypeptides and uses therefor | |
US20030143632A1 (en) | Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic and other uses |